


DIABETES

The Journal of the American Diabetes Association

INDEX

BY SUBJECT AND AUTHOR




VOLUME 9

1960

113609

Copyright 1961, by American Diabetes Association, Inc.



SUBJECT INDEX 1960

This index covers all reading matter in Volume 9 of DIABETES. Entries marked with an asterisk (*) indicate material which appeared in the ABSTRACTS only. The author index appears on page 22.

A

ABORTION

See also Fetus; Pregnancy
and glucose metabolism, 466-469
and prediabetes, *334, *423, 469

ACETATE

liver protein uptake, *514
metabolism, *425
in mammary glands, lactating, *332

ACETONE BODIES. See Ketone bodies

ACID. See specific acid

ACIDOSIS, diabetic

See also Ketoacidosis
in animals, species differences, 486, 487
and atherogenesis, *334
coma, 293
and emotional instability, *232
and gastrointestinal hemorrhage, 94
hepatomegaly, *232
and hyperlipemia, 482, 483
and insulin, *155, 245-248, 293, *336
and mucormycosis, 143-144
after myocardial infarction, *426
after phenethylbiguanide, 217, 220
pregnancy onset, 296
and renal function, 347, 350
and salicylate ingestion, 416
and transient ascites, *232
treatment of severe, *155-156

ACROMEGALY

and carbohydrate tolerance, 460
and growth hormone, 460-464
and insulin, 245, 247, 459-465, *514
and temporary diabetes, 374

ADAPTATION

to glucagon treatment, 60, 278, 283
to hyperglycemia, 60, 278, 283, 288
liver enzyme activities, *426

ADDISON'S DISEASE, *148, *231

ADENOSINE DIPHOSPHATE, and guanidines, 171

ADENOSINE TRIPHOSPHATASE, 174-177

ADENOSINE TRIPHOSPHATE

formation, 170-171
and insulin, 179, *421
and protein synthesis, *514

ADRENAL GLANDS

cortex, 43-46
aldosterone secretion, *78, 493
function, and phenethylbiguanide, 215
and glycosuria, 394
hormones, 355

See also specific substances
hyperplasia, in newborn, *338
and salicylates, 416-417

steroids, 368, 493
and insulin effects, 247-248

See also specific steroids

and glucose, 368
tolerance, 289
transport and phosphorylation, 251-253

and growth hormone, 38-47
hyperfunction. See Cushing's disease
and hyperglycemia, postoperative, *512

in hyperlipemia, 135
and hypothalamic lesions, *155
insufficiency. See Addison's disease
interrenal, in amphibians and reptiles, 321, 322

medulla, 289
in childhood hypoglycemia, *232
and liver phosphorylase, *154
steroid release after sulfonylureas, *231

in pregnancy, 368, 493
tumors, *78
and juvenile diabetes, 350

ADRENALECTOMY

glucose uptake after, 251-253
of lenses, *233
and liver phosphorylase, *154
after epinephrine and glucagon, *155

after glucose, *154
after insulin, *155
steroid clearance after, *333

ADRENALIN. See Epinephrine

ADRENOCORTICOTROPIC HORMONE

and glomerular filtration rate, 368
and hypoglycemia, *336
in infants, *423
spontaneous idiopathic, *426, *509
and phenethylbiguanide response, 215
and plasma cortisol levels, 355

AGE

See also Diabetes mellitus, childhood;
in elderly; juvenile

and amyotrophy, *333
and blood citric acid levels, *237
and complicating disease, *79, *232, 348, 351
hyaline islets, *421
of second leg, 101
and conjunctiva, arteriolar-venular ratios, 442-445
and diabetes incidence in Germany, *79
and emotional factors, *148, *338
and employment, 305
Netherlands study, 132
and glucose tolerance test, *421
and cortisone, 376, 384
and hepatotoxicity of oral sulfonylureas, 371
and insurability, 495, 496, 497
juvenile diabetes defined, 345, 346
of menarche, 346, *421
of menopause, *421
and "middle of road" policy, *234
and myocardial infarction, *426
triolein tolerance curves, *513
and obesity, demarcation, 109
and phosphorylative capacity, 170
in pregnancy, *78
and glucosuria, 363, 365, 467-468
and serum magnesium levels, *421
and spontaneous diabetes in dogs, 486-487

ALBUMIN

deficiency in nephropathy, *428
insulin inhibitor site, 246-247
serum levels, 482-483
and diet, 317
fatty acid binding, 173
urinary, in malabsorption, 16

ALCOHOL

fermentation, and glucagon, *511
sensitivity after chlorpropamide, *151

ALDOSTERONE, secretion

and adrenal adenoma, *78
and metabolism in pregnancy, 493

ALGINIC ACID, sulfated, and atherosclerosis, 291

ALLOXAN. See Diabetes mellitus, alloxan-induced

AMAUROSIS, diabetic, *74

AMERICAN DIABETES ASSOCIATION

Affiliate Associations
Detection drives, 81, 160, 243, 343, 438

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

SUBJECT INDEX 1960

news, 82, 161, 244, 343, 439-440, 521-522
 annual banquet, 283, 431-432
 highlights 238, 433
 annual meetings
 twentieth, 80-81, 158, 238-241, 341, 430-437
 business, 434-436
 elections, 341
 Executive Director's report, 435
 President's Address, 431-432
 registration figures, 341
 scientific sessions, 80, 158, 238-241, 430
 Secretary's report, 434
 special sessions, 430-431
 Treasurer's report, 434-435
 twenty-first, 437, 517
 twenty-second, 438, 517
 Banting Memorial Lecture, 80, 158, 345-355
 of British Diabetic Association, 440
 Banting Memorial Medals, 433
 Board of State Governors, 518
 Committees (1960-1961), 518-520
 on Employment, 303
 Informational Committee on Oral Hypoglycemic Compounds changed to Committee on Oral Hypoglycemic Compounds, 160
 Nutrition and Metabolism, Symposium, 440
 Scientific Exhibits, 243
 on Statistics, 139-142, 500-503
 Subcommittee on Standardization of Committee on Professional Education changed to Subcommittee on Definition and Classification of Committee on Professional Education, 160
 Council
 Bylaw amendments, 159
 elections, 341
 Diabetes Week, 81, 160, 243, 343, 438
 essay contest, 80-81, 159-160, 437, 521
 1959-1960 winners, 436-437
 FORECAST
 "Exercise, Calories, and Diabetes," 342
 oral compounds article, 81
 Summer Camps for Diabetic Children, 160
 Identification Card, 161
 International Diabetes Federation, fourth congress, 81, 160, 243, 343, 438
 Journal
 editorials
 Diabetes and Mucormycosis, 143-145
 Exacerbation of Diabetes by Excess Insulin Action, 328-330
 Fat Content of the Diabetic Diet, 145-146
 Histology of Small Vessel Disease in Diabetes, 503-505
 Insulin and Pinocytosis, 70-71

Salicylates and Carbohydrate Metabolism, 416-418
 new editor and chairman, editorial board, named, 159
 Lilly award, 159, 342, 433, 438, 520-521
 in memoriam
 Dillon, Edward S., 228
 Hart, James F., 72
 Palmer, Lester J., 331-332
 Wilder, Russell Morse, Sr., 419-420
 Zoja, Luigi, 229
 and National Institute of Arthritis and Metabolic Diseases, Diabetes Program Directors' Workshop, 81
 proceedings, 405-415
 necrology, 82, 162, 344, 522
 new members, 81-82, 160, 243-244, 343, 438-439, 521
 news notes, 82, 161, 244, 343-344, 440, 522
 obituaries. *See* American Diabetes Association, necrology
 personals, 82, 162, 244, 344, 522
 postgraduate programs, 82, 159, 161-162, 242, 342, 343-344, 515-517
 publications
 abstracts, scientific session papers, 239
 binders, 81
 Diabetes Guide Book for the Physician, 521
 Teaching of Diabetes in Medical Schools, 405-415
 Teaching and Research in Diabetes, 81, 160, 243
 research fellowships, 159, 242-243, 342, 438
 scientific programs
 exhibits, 243
 list of papers, 239-241
 AMINO ACIDS
 of brain substances, *427
 after carbohydrate intake, 105, 177
 and plasma levels, *79, 183-184
 essential, and growth rate, 214
 in hypoglycemia, *79, *427
 insulin molecule sequence, *422
 intra-abdominal mesothelial-cell sarcoma levels, *79
 and lipid mobilization, 136
 liver protein uptake after glucose-6-phosphate, *514
 P-AMINOBENZOIC ACID, acetylation, *234
 and serum insulin activity, *153
 AMYLOIDOSIS
 differential diagnosis, *426
 and spontaneous diabetes in animals, 486-488
 AMYOTROPHY, diabetic, *333
 ANEMIA
 hemolytic, after metahexamide, 370
 glucose-6-phosphate dehydrogenase deficiency, 28

hypochromic, in malabsorption syndrome, 15
 and vision impairment, *74
 ANEURYSMS, and retinopathy, 9-13, *156, 350, 352
 ANGINA PECTORIS
 and hypoglycemia, *335
 and prediabetes, 375
 ANOREXIA
 in acidosis coma, 293
 after glucagon, 278-285
 after phenethylbiguanide, 183, 221
 ANTHRONE BLOOD SUGAR METHOD, *336, *429
 ANTIBODIES, insulin
 antigen binding kinetics, *422
 assay technics, 254-260, 325-326
 cross reactions, 254-256, *422
 in infections, 247
 after insulin therapy, 246, 254-260
 in juvenile diabetes, 350
 plasma effects, 246, 256
 species-specificity, 254, *422
 and steroid therapy, 248
 AORTA, complications, *74, 349
 APPETITE
 after glucagon treatment, 281
 and growth hormone, 39-40, 273
 psychogenic factors, 166
 and spontaneous diabetes in animals, 486
 ARABINOSE
 diaphragm space after phenformin, 168
 intracellular permeation, and insulin, A-chain, *509
 metabolism of radiolabeled, *514
 ARACHIDONIC ACID, serum levels, *429
 ARTERIOSCLEROSIS
 cerebral, and leg lesions, 102
 coronary, electrocardiograms in hypoglycemia, *335
 heart disease, 504
 mortality rates, 141
 of major arteries, incidence, 504
 renal, and spontaneous diabetes in dogs, 487
 serum lipids, *429
 polyen-acids content, *513
 and vasculograms, in diabetes, *335
 ARYLSULFONYLUREAS
See also specific substances
 patient selection, *337
 phenethylbiguanide additive effects, 222-224
 and thyroid function, *337
 ASCORBIC ACID
 adrenocortical depletion by salicylates, 416-417

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
 July-August, 245-344

March-April, 83-162
 September-October, 345-440

May-June, 163-244
 November-December, 441-522

SUBJECT INDEX 1960

enzymatic conversion of glucuronolactone to, *507-508
urine levels and glucose-oxidase test, *428

ASPIRIN

See also Salicylates
and blood sugar, 392, 393, 416
and plasma 17-hydroxycorticosteroid levels, 417

ATHEROSCLEROSIS

coronary, *74
ballistocardiogram, *78
electrocardiogram and blood potassium, *336
and hypoglycemia, *334-335
and diabetes, *334
control, *334
diets, *425, 499, *507, *510
emotional factors, *334, *338
and hypercholesteremia, *507
and lipid metabolism, *510
and sulfated alginic acid, 291
triolein tolerance curves, *513

B

BACTERIURIA, in diabetes, *151

BANTING MEMORIAL

lecture, 80, 158, 345-355
of British Diabetic Association, 440
medals, 433

BENEDICT'S TEST, and ascorbic acid levels, *428

BIGUANIDES

See also specific substances
and guanidine responses, 180
in juvenile diabetes, 345
insulin combination, 350
patient selection, 293

BILE, production and hepatic bypass, *422

BLOOD, *337, *429

See also Blood sugar; Plasma; Serum
arteriovenous fatty acids, 117
-brain barrier, and sugar transport, *513
calcium levels, of newborn, *234, *338
after chloride therapy, *155
citric acid levels after insulin and tolbutamide, *237
coagulability and emotional stress, *338
fructose, 190-193
groups, and diabetes mellitus, 20-24
hematocrit, *156
in burn-stress pseudodiabetes syndrome, *507
in juvenile diabetes, 345-346, 481-484
ketones. See Ketone bodies
lactate levels, *148
and phenethylbiguanides, 186, 187, 190-193, 200, 212, 216, 224

in malabsorption syndrome, 16
potassium levels, 224
in acidosis, *155
and electrocardiography, *335
of newborn infants, *338
pyruvate, 186, 187, 190-193, 200, 212, 216
sodium levels, 224
urea nitrogen, 198
after cortisone, *338
and growth hormone, 273, *333
volume, *156
in diabetic children, *335

BLOOD FLOW. See Circulation

BLOOD PRESSURE

See also Hypertension
and atherogenesis, *334
and bulbar conjunctiva, 442
and functional microangiopathies, *339
and insurability, 495
in malabsorption syndrome, 16

BLOOD SUGAR

See also specific conditions
in acromegaly, 459-462
after alloxanization, 114, *427, 472, 490-493
in amphibians, 319-321
arteriovenous differences, *74, *148, 202, 205, 216, 248, 286, *336, 459, *512
in asymptomatic diabetes, 83-88
after brain stem damage, *236
and "brittle" diabetes, *148
and bulbar conjunctiva, 442-445
and carbon dioxide concentrating power, *232
after carbutamide, 67, 68
in cerebrovascular accidents, 49
after chlorpropamide, 112, 226, *334
and shock, *423
after cortisone, 53-61, 264-270, *427
and diabetes incidence in Basutoland, *428
dietary factors, 30, 51, 219
See also Diet
carbohydrate types, 387-388, 390
after sorbitol ice cream, 499
and diethylthiocarbamate, 63
and electrocardiography, *335
fasting, *148, 186-193, 195, *236, 256-260, 296, 360-361, 392, 416
in diabetes-like states, 289
and forearm glucose uptake, *74
and latent diabetes, 293
sex differences, 387-388
in vulvitis, *237
and weight, 219
after fructose, 190-193
after glucagon, 32, 53-61, *157, 278-285, 288-289, 320-322, 357
and glucose metabolism, *74, *148, *152, 286, 356-362, 387-388, 447-453
and glucose-6-phosphatase, 176
and glycolytic infiltration of cells, 472-480

and growth hormone, 39-46, 265, 274, 275, *336, *427
homeostasis, 286-291
role of kidney, 174
in "hunger diabetes," 288
hypoglycemia, *423
idiopathic spontaneous, *509
after hypophysectomy, *237, *336
in hypopituitarism, 274
after hypothalamus damage, *236
and insulin. See Insulin
and insurability, 495
and interrenal glands, 321
and leucine sensitivity, *509
and liver, 286, *510
in lizards, 320
in mammals, 321-322
in maturity-onset diabetes, 257, 259-260
and mental state, *232
and metahexamide, 266
in myocardial injury, *513
newborn infants, *338
after pancreatectomy, 265, *427
normal and diabetic differences, 202-206
after phenethylbiguanide, 118-125, 174-177, 186-193, 195, 198, 200, 209-213, 216-224, *508
and pancreatic digestion, 37
See also Diet
postoperative, *512
and pregnancy, *157, 490-493
diabetes onset in, 296
and fetal mortality, 492
regulation during sleep, *512
in reptiles, 319-321
and salicylates, 392, 393, 416
and skin sugar content, 48-52
and splanchnic sugar output, 311-317
and succinic dehydrogenase activity inhibition, 176
and sulfonylureas, *76, *427
and temperature, 321
tests, *236, 324-327, *423, 467, *512
anthrone method, *336, *429
-aqueous ratios, *76
and carbohydrate intake, 387-388
colorimetric, modification, *233
enzymatic method, *336
fluctuations with time, 293
Folin-Mahros, 396
in glaucoma, *507
glucose-oxidase method, *76
and ascorbic acid, *428
Hagedorn-Jensen method, *429
postprandial, 49, *231
reliance, 293
Somogyi method, 472
Nelson adaptation, *76, 183, 482
after tolbutamide, *79, 83-88, 266, 356-362, *427
in turtle, 320
variations, 223
and constant diet, 245

BLOOD VESSELS
See also specific sites
arterioles, 350, 503
renal hyalinization, *339

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

SUBJECT INDEX 1960

- venule ratio, and retinopathy, 441-446
and beta cell defective mechanism, 375
capillaries, 9-13, 503
"fat emboli," 10
after hypophysectomy, *156
submucosal, and gastrointestinal hemorrhage, 95-96
cerebrovascular accidents, 102, 350
complication development, *427, *507
calcification, 349, 350, 496-497
and duration of illness, 1-8, 348-351
and erythrocyte aggregation, *149
genetic trait, 353
and insurability, 495-497
and lipid metabolism, *73
and neurologic disease, 504
ocular. *See* Eyes; Retinopathy
potential reversibility, 353
in pregnancy, 347, 350-354
sex differences, 349
small vessel disease, *339, 503-505
of bulbar conjunctiva, 441-446
microaneurysms, 9-13, *156, 350, 352
and types of diabetes, 349-350, 373, 375
vasculograms, *335
iatrogenic production of damage, 350
in juvenile diabetes, 348-351
mucormycosis, 143
prediabetes, 374, 376
venules, 503
after hypophysectomy, *156
- BODY**
fat content, 125
See also Obesity; Weight
in newborn, *510
growth
and carbohydrates, complex, 214
after cortisone, *509
after glucagon, 280, 283
after growth hormone, 272, 276, *333
after ovarian hormones, *509
patterns in juvenile diabetes, 345, 346, 351-353
after phenethylbiguanide, 223
plasma factor, *233
after thyroxine, *509
weight. *See* Obesity; Weight
- BONE**
demineralization, 17-18
fractures, and temporary diabetes, 374
in juvenile survivors, 348
and their children, 352, 353
pain, and steatorrhea, *425
and malabsorption syndrome, 15-18
- BOOK REVIEWS**
Arterial Embolism in Limbs, by A. L. Jacobs and C. G. Rob, 330
Arterial Wall, edited by Albert I. Lansing, 505
Chemistry of Pancreatic Diseases, by Harris Busch, 147
- Diabetic's Handbook, by Anthony M. Sindoni, Jr., 506
Hormones and Atherosclerosis, edited by Gregory Pincus, 506
Human Nutrition and Dietetics, by Sir Stanley Davidson, A. P. Meiklejohn and R. Passmore, 505
Nutritional Diagnosis, by Grace A. Goldsmith, 72
Pancreatitis. A Clinical-Pathologic Correlation, by Herman T. Blumenthal and J. C. Probst, 330
Peripheral Vascular Diseases, by Travis Winsor, 418
Preventive Medicine, edited by Herman E. Hilleboe and Granville W. Larimore, 230
Pyelonephritis, by Fletcher H. Colby, 505
Reversible Renal Insufficiency: Diagnosis and Treatment, by Donald H. Atlas and Peter Gaberman, 418
Thirst, by A. V. Wolf, 146-147
Treatment of Diabetes Mellitus, by Elliott P. Joslin, Howard F. Root, Priscilla White, and Alexander Marble, 147
- BRAIN**
birth injury, *233
-blood barrier, and sugar transport, *513
blood flow after eating, *512
and blood sugar level, *236, 286
complications, 102
in juvenile survivors, 348, 351
ethanolamine, *427
phosphate uptake, *231
and hypoglycemia, *73, *232, *427
mucormycosis, 143, *339
phosphorylcholine formation, *231
- BRAIN STEM**, and blood sugar, *236
- BROMSULPHALEIN**. *See* Sulfobromophthalein
- BURNS**
pseudodiabetes syndrome, *507
and temporary diabetes, 374
- BUTYLAMINO BENZENESULFONYL-UREA**. *See* Carbutamide
- 1-BUTYL-3-TOLYLSULFONYLUREA**. *See* Tolbutamide
- BZ-55**. *See* Carbutamide
- C**
- CALCIUM**
balance after strontium lactate and testosterone enanthate, *335
blood levels, newborn, *234, *338
in malabsorption syndrome, 16
for oxidation by aging, 170
- retention, after growth hormone, 273, *333
- CANCER**
and diabetes, *150, *152, *336
insipidus and mellitus coexisting, *237
spontaneous in dogs, 487
in thirty-year survivors, 351
Walker implant suppression, *336
endometrium glucose tolerance, *421
of pancreas, *150, *152, *335
uterus body, and prediabetes, 375
- CARBOHYDRATES**
complex in "sparing protein," 214
dietary intake, 6, 105, 177, 350
criteria for, 389-390
and glucose-tolerance test, 387-388, 390
and ketonuria, 218
after phenethylbiguanide, 195
prescription, 145
vegetables, 4
growth hormone effects, 274-276, *333
and Krebs cycle function, 287-288
metabolism, 273-276, 288, *333, *422, 478
in acromegals, 459-465
in amphibians, 318-322
and insulin, 138, *157, *234, *236, *333
latent diabetes, 301
and liver enzymes, *426
in neoplastic disease, *73
obese-hyperglycemic syndrome, 63
in pentosuria, *509
after phenethylbiguanide, 197-198
precursor for glyceride-glycerol, 262
in prediabetic stage, *76
in pregnancy, 142, *148, *157, *234, 296
radiochromatography, *232
in reptiles, 319-322
and salicylates, 416-418
and skin sugar test, 50-52
sulfonylurea compounds, *508
and vulvitis, *237
and muscle glycogen, 278-288
and plasma amino acids, *79
and postoperative care, *514
privation in diabetes-like states, 288, 290
protein-bound, *149
in late complications, *151
and spontaneous diabetes in sheep, 486
starch, sucrose replacement, 214
synthesis by intestinal microflora, 214
and tolbutamide therapy, *234
in asymptomatic diabetes, 83-88
tolerance, 460
criteria, 389-390
wastage, and phenethylbiguanide, 216, 217
- CARBON DIOXIDE**
and blood sugar, *232
homeostasis, of neonate, *234
output, and glucose utilization, *73

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

SUBJECT INDEX 1960

- from pentoses, variations, *154
serum content, 293
- CARBON TETRACHLORIDE**, and hepatic glycogen content, 126-128
- CARBUTAMIDE**, *75
absorption rates, 455-458
and hepatic glycogenolysis, *425
long-term treatment, 68
and late failures, *510
in obese-hyperglycemic syndrome, 63-69
sensitivity reactions, species differences, 179
solubility, and pH, 456
and thyroid function, *337
and tolbutamide, comparison, 455-458
toxicity, *153, 370
- CARCINOMA**. *See* Cancer
- CARDIOVASCULAR DISEASE**. *See* Heart Disease
- CASE REPORTS**
cerebral mucormycosis, *339
gastric hemorrhage in diabetic coma, 94
hypoglycemic shock from chlorpropamide, 110
insulin-resistant diabetic coma, 97
juvenile diabetes
and phenethylbiguanide therapy, 222-223
of thirty-nine years' duration, 104
malabsorption syndrome and diabetes, 106-108
and diarrhea, 14-16
- CASEIN**, 214
- CATAMENIA**, diabetic, *421
- CATARACT**, *150
and duration of illness, *234
galactose, *152
in horses, 486
in subthreshold diabetes, *78
- CHILD**
See also Infant
diabetic. *See* Diabetes, in childhood
hypoglycemia, *75
spontaneous, *232
idiopathic, *426, *509, *514
identification, *148
nutrition, of American, 372
and parental diabetes, *75, *332, 346-347, 351-354, 375
See also Pregnancy
phenethylbiguanide for seizures, 223
phenylketonuria, *75
- CHLORIDE**
deficiency in diabetic acidosis, *155
excretion after phenethylbiguanide, 195-200
homeostasis in neonate, *234
serum levels in burn-stress pseudodibetes, *507
- CHLOROTHIAZIDE**, in juvenile diabetes, 353
- CHLORPROPAMIDE**
absorption rate, 455, 458
and carbutamide, 455-458
dosage, *76, *514
and alkaline phosphatase levels, *422
and hypoglycemic shock, 110-113, *423
and insulin, *339, 455
and insurability, 496
and liver function, *334, 370, 371, *422
and methexamide, 28, 455, 458
and pancreatic cells, 266-267
patient selection, *424, *514
adult diabetes, *75, *153, *339, *508
potency, *234, 454-458
prolonged therapy, *334
reactions, species difference, 179
serum half life, 112
side effects, *339, 370, 371
solubility, and pH, 456
and tolbutamide, *76, *149, *334, *339, *426, 455, 456, *508, *514
toxicity, *234, *339, 370, *514
hepatic, 370, *422
and glucose-6-phosphate dehydrogenase, 331
- CHOLESTEROL**
and atherosclerosis, 146, *507
and diabetes complications, *510
esters, 482-483
polyen-acid content, *513
in pregnancy, 468
fatty acid lowering effect, 146, 499
in glycogen disease, *508
hypercholesterolemia, 146, *507
familial, *233
and nephropathy, *429
in obese-hyperglycemic syndrome, 68
vitamin A tolerance test, 295
liver degradation defect, *429
in malabsorption syndrome, 16
phospholipid ratio, *73
in juvenile diabetes, 482-483
serum levels, 146, *507
and glucose tolerance, 466-468
and growth hormone, *333
and protein intake, *73
water deprivation, *231
after sulfonylureas, *337
synthesis in diabetic nerve and spinal cord, *335
- CHOLINE**, phosphatidyl, after insulin, *231
- CIRCULATION**
cerebral, after eating, *512
collateral, and obliterative changes, 504
cutaneous, in hypoglycemia, *73
fluid loss in acidosis, *156
and glucose utilization, *74
- limb, *74
and insulin, *336
in acromegaly, 459-465
liver, *77
after glucagon, *429
after phenethylbiguanide, 209, 213
after myocardial infarction, *426
reflex absence, *514
renal and microangiopathy, *339
- CITRATE**
growth hormone effects, 274, 275
and muscle response to insulin, *336
and phenethylbiguanide metabolism, 171
- CITRIC ACID**
blood levels after insulin and tolbutamide, *237
and growth hormone, 275
and phenethylbiguanide, 186-193
- CLINISTIX TEST**, and ascorbic acid, *428
- COBALT**, pancreatic responses, 57, 59-60
- COMA**
and acidosis, 293
and duration of illness, 5-7
and gastrointestinal hemorrhage, 94-96
hypoglycemic, 111
glucagon termination, *421
and insulin resistance, 97-99
in juvenile diabetes, 345, 348
in pregnancy, 301
and toxemia, *423
and renal cortical necrosis, 423
and salicylate poisoning, 416
in sheep, 486
in staphylococcal pneumonia, 350
- CONGENITAL ANOMALIES**, 232, *423, 466
prediabetes, 373, 375
prophylaxis, *233, *335, 376
in second generation, 351, 352
- CONVULSIONS**
and hypoglycemia, *336
and phenethylbiguanide, 224
and toxemia of pregnancy, *423
- CORONARY ARTERY**
atherosclerosis, *74, *78
and blood potassium, *336
and sulfated alginic acid, 291
and vitamin A, 295
and emotional factors, *338
insufficiency, and hypoglycemia, *334
in juvenile diabetes survivors, 349
occlusion, in newborn, 352
proliferative endothelial lesions, 504
- CORTISOL**. *See* Hydrocortisone
- CORTISONE**
and blood urea level, *338
glucose tolerance test, *73, 375-376
and parental diabetes, 379-385
and glycosuria, 394

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

SUBJECT INDEX 1960

- Walker carcinoma implantation, *336
- hyperglycemia, 264
and epinephrine, *156
and glucagon, 53-61, *156, 264
for hypoglycemia in infants, *423
and insulin, in diabetes reversal, 350
and lipid mobilizer, 135
and liver glucose 6-phosphatase, *429
and mammary gland growth, *424, *509
and pancreatic islets, 264-271
and potassium retention, 273
and sulfonyleureas, *427
and thyroid hormone metabolic effects, *509
- CREATININE, *337
excretion after phenethylbiguanide, 195-200
- CUSHING'S SYNDROME
fasting glucose levels, 289
insulin requirements, 245, 248
and temporary diabetes, 374
- D**
- D-860. *See* Tolbutamide
- DBI. *See* Phenethylbiguanide
- DECAMETHYLENEDIGUANIDINE,
toxicity, 121, 178
- DEHYDROASCORBIC ACID, *77
- DEXAMETHASONE, for pemphigus vulgaris, *334
- DEXTRAN, in acidosis, *156
- DEXTRIN, 105, 177, 214
- DIABETES INSIPIDUS, and diabetes mellitus coexistence, *237
- DIABETES MELLITUS
See also specific conditions; specific hypoglycemic agents
and acromegaly, 245, 247, 374, 459-465, *514
and Addison's disease, *148, *231
administrative aspects, *338
age of onset, 15-18, *152, 257, 259-260, *508
and degrees, characteristics, 349
and fatty livers, *76
and Glipasol, *74
and growth, 220, 347
and leg lesions, 100, 101
after menopause, *421
and metabolism, *75
presence from birth, 376
and puberty development, 346
transitory, 301
alloxan-induced
acetoacetate metabolism, *425
amyotrophy, *333
anaerobic glycolysis, *334
butyrate metabolism, *425
cholesterol turnover, *429
and diphenylthiocarbazon, *74
and Eck fistula, *77
glucagon, and metaglucon, 278-285
and glucose, 314
glyceride-glycerol formation, 262
lenses uptake, *233
phosphorylation, 250-253
transport, 250-253
liver, and insulin, *155, *429
and mucormycosis, 144
muscle oxygen consumption, *336
and offspring, 114-117, 396-404, *427, 490-493
See also Fetus; Pregnancy
and pancreatic islets, 283
glycogenic infiltration, 471-480
sulfhydryl content, *77
and phenethylbiguanide, 167, 207, 221
retinopathy, *334
splanchnic sugar output, 311-317
and spontaneous in animals, 485-489
subdiabetic, and tolbutamide, *236
amputation, 100-103
and atherogenesis, *334
See also Atherosclerosis
blood sugar. *See* Blood sugar
brittle, *148
and phenethylbiguanide, 220-224
insulin combination, 221
carbohydrate tolerance criteria, 389-390
and carcinoma of pancreas, *150, *152
childhood, 222, 345-355
dietary intake, 6, 372, 378
and nondiabetic siblings, 347
psychological problems, 351
renal disease, 349
and microangiopathy, *339
summer camp operation, *508
complications, 1-8, *74, *75, *79, *153, *512
See also specific conditions; specific sites
counseling, *233, 411-412
and diabetes insipidus co-existing, *237
Diabetes Week, 81, 160, 243, 343, 438
diagnosis, 293, 379-385, 466-467, 469
and adrenal tumors, 350
"benign" glycosuria, *78
burn-stress pseudodiabetes syndrome, *507
cephalin flocculation test, 482
criteria, 389
obesity, *78
by ophthalmologist, *231
screening tests, *237, *507
of subthreshold, *78
triad, 345-346
two-hour postprandial method, *513
and diarrhea, 14-19, *74, *78, 106-108, 221
duration, *150, *338, 348-350
and glomerular capillaries, 105, 349
and glucose-6-phosphate dehydrogenase activity, 371, *429
and hyperlipemia, 482
and insurability, 495
and late lesions, 1-8
See also specific sites
and management, 1-8, 187, 195, 223, *234, 350-351, 371
See also specific substances
renal arteriolar hyalinization, *339
and serum magnesium levels, *421
thirty years, 348-351
thirty-nine years, 104-105
employment, 502
and absenteeism, 305-308, *429
careers, 351
counseling for, 412
by du Pont de Nemours, 303-310
in Netherlands, 129-134
"epinephrine," 288-290
etiology, *231, *332, 374, 488
familial history, *332, *333, 379, 469, *507
heredity, *332, 351
Mendelian recessive, 352
gastric acid secretion, *77
genitourinary aspects, *153
glucagon, *236, 278-285, 288-290
glucose-6-phosphate dehydrogenase, 287, *429
erythrocyte, in sulfonyleurea hepatotoxicity, 370-372
and hemochromatosis, *424, *507
hepatic glucokinase activity, 287
"hunger," 288, 386
and hyaline islets, *421
identification, *148, 412
incidence, *231, 351, 375
See also Diabetes, statistics
and age, *426
in Basutoland, *428
in Germany, *79
in Ghana, *424
in Hawaii, *79
in Hungary, *322
increase among blind, *428
and infections, *153, *232, 245, 247, 248, 293, 307, 308, 348, 354, 374, *424
bacteriuria, *151
fungus, 143
juvenile, *74, 104-105, *335
acidosis, *232
and adolescence, *148, 348
in adults, and insulin, therapy plan, *424
ballistocardiogram, *78
blood lipids, *335, 481-484
at Camp NYDA, *335
and chlorothiazide, 353
coma, 345, 348
defined, 345
dietary control, 6, *335, 350, 372, 378
electroencephalogram, and Dilantin, 223
and family size, 346-347
growth hormone, *237, *336, 346
height, 346
and hypoglycemic preparations, *149
hypophysectomy, *237, *336

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

SUBJECT INDEX 1960

influence on second and third generation, 345-355
and insulin, *149, 220, 221, 345, 347, 350, *424
resistance, 245
insulinitis in early, *427
and insurability, 496
life span, 104-105, 348-351
malignant lesion development, 349-350
mother and daughter growth, 352, 353
nocturnal hyperglycemia, 345
pancreatic tissue transplant, 351
and phenethylbiguanide, 220-221, *237, *424
prepuberty onset, 346, 350-351
progression to total, 345-346, 352-353
protein levels, 481-484
sex differences, 346-347
and siblings, 346, 351, 375
diabetic, *332
transient ascites, *232
labile, 221
and insulin, *424
resistance, 245
and phenethylbiguanide, 195, 224
latent, 293
See also Diabetes, prediabetes
and gestational onset, 296-302
after growth hormone, 275
and liver injury, *510
life insurance, 139
requirements, 494-495
and malabsorption syndrome, 14-19, 106-109
metaglucacon, *237, 278-285
mild, 495
and cortisone glucose tolerance, 376
and growth hormone, 274
mortality. See Mortality
and myocardium, *513
infarction, *426
and nodular lesions, *338, 349, *426
and osteoporosis, *335
paternal, and congenital anomalies, 351, 352, 375-376
and pemphigus vulgaris, *234
and pituitary gland, *508
tumor, *153
and porphyria cutanea tarda, *512
prediabetes, 293
cortisone response, 379-385
and glucose metabolism, 466-470
prevasculopathy, 374, 376
in pregnancy. See Pregnancy
remission, *73, *231, *335, 345, 350, 353
renal function, *339, 347
basement membrane thickening, *425
research, *76, 411-414
species differences, 178-179, 182, 269, 485-489
spontaneous, in animals, 485-489
stable, *148, 187
and forearm glucose utilization, *74

and oral hypoglycemic agents, *152, *236
and phenethylbiguanide, 195, 205
statistics, 139-142, *231, 500-503
by age, 140, 141, 501, 502
by area, 139, 140, 500
in Asia, *231
Canada mortality, 139, 142, *231, 500
in Central America, *231
comparability ratios, 141
by countries, 139, 142, *231, 500
in England and Wales, 142, 500, 502
by geographic division, 140, 501
Joslin Clinic, 503
by life insurance policy holders, 139, 497-498, 500
by marital status, 501
by race, 140, 501
by sex, 140, 141, 500, 501
socio-economic groups, 501-502
in South America, *231
United States, 139, 140, *231, 480, 500-501
and steatorrhea, 14-16, *425, 487, *510
"steroid," 288-290
and chlorpropamide, *427
stress effects, 394-395
and tolbutamide, *427
Walker carcinoma implantation, *336
subthreshold, *78
surgery. See Surgery
teaching and training, 405-415
temporary, 374, 376
after total pancreatectomy, 221
transitory, 296-302
treatment, *512
See also Specific substances
dietary. See Diets
education of patient for, 411-412
in fasted animals, 179
injection sites, and dosage, 248
"margins of safety," 292-295
"middle of road" policy, *234
periodic visit to physician, 292-293
persistence of response, *76, 250
by pituitary gland infarction, *509
Rauwolfia alkaloids, *74
strontium lactate, and calcium balance, *335
and survival, 104-105, 348-351, *512
testosterone enanthate effects, *335
therapy selection, *152, *337, *424, *508, *514
and zinc excretion, *74
trioclein tolerance curves, *513
uncontrolled, 198, *234
and optic neuritis, *153
unstable, 222, 223, *237, 328
and hypoglycemic preparations, *149
nondiabetic complications, 222
and phenethylbiguanide, *508

DIARRHEA

in juvenile diabetes, *74

malabsorption syndrome, 14-16, 106-108
and phenethylbiguanide, 221
postprandial exacerbation, 14
and steatorrhea, 14
and subthreshold diabetes, *78

DIET

in acidosis coma, 293
and blood lipid levels, *510
and blood sugar levels, 30, 51, 387
during sleep, *512
and pancreatic digestion, 37
variations on constant diet, 245
caloric intake, 6, 148, 195, *337, *424, *510
and ketonuria, 218, 220
and obesity, 274
and requirements, 138, 145
and skin tests, 51
carbohydrate intake, 105, 145, 218, 387, *425, 499
criteria, 389-390
and phenethylbiguanide, 195, 218
prior to glucose tolerance tests, 386
vegetables, 4
casein-sucrose ration, and growth, 214
cataractogenic galactose, *152
corn oils, 146, 214
corn starch, 214
cotton-seed oil, 146
dextrin, 105, 177, 214
diabetes control, *73, 145, *149, *157, 293, *511
and atherosclerosis, *425, 499, *507, *510
and chlorpropamide, *153
and food habits of indigent, *78
"free," 1, 4, 378
and insurability, 496
juvenile, 6, *335, 350, 372, 378
in nephropathy, 4
patient education, 411, 412
and sulfonylurea compounds, *424
fat intake, 37, *150, 425, 499, *510, *511
and emotional factors, *338
hepatic lipogenesis, 415
optimum, 145-146
vegetable, *510
fructose, 499
and glucose, 499
tolerance, 19, 469
and glycoproteins, 317
hypoglycemia, *509
phenylalanine-deficient, *75
and ketosis, 293
leucine, *336
oatmeal, 19
and plasma fatty acids, nonesterified, 274, *337
potassium intake, 195
in prediabetics, 376
protein, *73, 145, 177, 317, 350, *425, 469, *511
in retinopathy, 4
rice, *152
Kempner's, *335
safflower oil, 482
sodium intake, 195, 214

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

SUBJECT INDEX 1960

- sorbitol, 499
sucrose, 37
 replacement of starch, 214
and vascular degeneration, *152, 376
vitamins, and growth rate, 214
and weight, 293
 gain, after tolbutamide therapy,
 *337
 reduction, 274, *424
- DIETHYLDITHIOCARBAMATE, and
 blood sugar, 63
- DIGUANIDINES, 180
 See also specific substances
- DILLON, Edward S., 228
- DIMETHYLDIGUANIDE, *76
- DINITROPHENOL
 and phenethylbiguanide, 170, 171
 and salicylate, 417
- DIPHENYLTHIOCARBAZONE
 and alloxan diabetes, *74
 pancreatic islet response, 32
- DIPHOSPHOPYRIDINE NUCLEO-
 TIDE, 170
 in protein synthesis, *514
- DIURESIS
 newborn infants, *338
 osmotic, in burn-stress pseudodiabetes
 syndrome, *507
 in prenatal care, 347
- "DUMPING" SYNDROME, and blood
 sugar, 360-361
- DU PONT DE NEMOURS AND CO.,
 INC., 303-310
- DWARFISM, diabetic
 daughter growth trend, 352
 obese, and insulin action, 346
- E**
- ECK FISTULA, and reverse, *77
- EDEMA
 and aldosterone-secreting adrenocorti-
 cal adenoma, *78
 and juvenile diabetes, *74
 newborn, transitory complications, 352
- ELECTROLYTES
 blood levels, *512
 after phenethylbiguanide, 222, 224
 in diabetic acidosis, *155-*156
 dietary intake and diabetes control,
 *511
 in newborn, *511
 on first day of life, *234
 and postoperative hyperglycemia, *512
 serum levels after insulin, *429
- ELECTRON MICROSCOPY
 beta cells, glycogenic changes, species
 differences, 471-480
 kidneys, *150, *426-*427
 in juvenile diabetes, 350
 of placenta in maternal diabetes, 352
- ELECTROPHORESIS
 immuno-assay technic, 325
 insulin, A and B chains, *150
 in juvenile diabetes
 lipoproteins, 482-483
 serum proteins, 482
 serum insulin-like activity, 326
- EMBRYOMEGALY, 114-117, 293, 346,
 352, 398-403, 466-470, 490-
 493
 See also Fetus
- EMOTIONAL FACTORS
 in adolescence, *148
 in atherosclerosis, *338
 of child, and parental diabetes, 351
 and diabetic instability, *148, *232
 in hypoglycemia, 329
- EMPLOYMENT
 and absenteeism, 305-308, *429
 careers, thirty-year survivors, 351
 and diabetes statistics, 502
 du Pont Company, 303-310
 job counseling, 412
 in Netherlands, 129-134
 in Postal, Telegraph and Telephone
 Company, 129-134
- ENCEPHALOPATHY, *73, *232
- ENDOCRINE GLANDS
 See also specific glands
 and lipid mobilization, 135-136
 metabolism during pregnancy, *234
 and spontaneous diabetes in dogs, 487
- ENZYME SYSTEMS
 acetyl Co A, *425
 in fatty acid synthesis, *156
 and growth hormone, 276
 activities
 beta, ductular and acinar differences,
 478-479
 and phenethylbiguanide, 174-177,
 180, 199
 blood sugar method, *336
 defect, and hepatotoxicity, 370
 and electron transport, 171, 180
 factor in cataract formation, *152
 and fatty acid synthesis, *156-*157
 and genetics, 206
 galactosemia heterozygous carrier,
 *424
 glucuronolactone conversion to ascor-
 bic acid, *507-*508
 lipolysis, and sulfated alginic acid, 291
 liver, and carbohydrate metabolism,
 *426
 poisons, and Krebs cycle, *427
- EPILEPSY, and maternal diabetes, *233,
 *334
- EPINEPHRINE
 and blood sugar, in amphibians and
 reptiles, 321
 after cortisone, 264-270
 "diabetes," 288-290
 and glucose metabolism by adipose
 tissue, 289, *422
- and glycogen, *156, 289, *508
hyperglycemic effects, *422
in idiopathic hypoglycemia, *426
and insulin, 248
liver responses, *156, 289, *422
 phosphorylase activity, *155
and potassium levels, *335
tolerances after phenethylbiguanide,
 215
- EPITHELIUM, DUCTULAR
 cell mitosis after sulfonylureas, 266-
 268
 glycogenic infiltration, 59-61, 264, 266,
 471-480
- ERYTHROCYTE
 and beta cell function, *509
 glucose-6-phosphate dehydrogenase,
 370-372
 genetic deficiency, 371
 intravascular aggregation, *149
 in retinal aneurysms, 10
 sensitized, in immuno-assay technic,
 325-326
- ESTROGENS
 and glucose, renal tubular reabsorp-
 tion, 368
 in juvenile diabetes, 350, 351
 in prenatal care, 347
- ETHANOLAMINE, and insulin, *231,
 *427
- ETHYLENEDIAMINE TETRA-ACE-
 TATE, and adipose tissue,
 325
- EXERCISE
 children, and phenethylbiguanide, 223
 and glucose, space diffusion estima-
 tion, *233
 and steroid clearance, *333
- EXTREMITIES
 in acromegaly, 459-465
 blood vessel complications, 100-103
 in juvenile diabetes survivors, 349
 obliterative disease, 504
 foot hygiene, 412
 glucose uptake, 51
 and blood sugar level, *74, *148,
 313, 316
 after growth hormone, 462-465
 left and right hand skin-surface-glu-
 cose test, 51-52
 leg lesions, in diabetic amputee, 100-
 103
 and hand lesions, 102
 motor palsies, *333
 nonesterified fatty acid concentrations
 after insulin, *425
 steroid clearance and exercise, *333
- EYES
 See also Retinitis, Retinopathy
 aqueous humor glucose determination,
 *76
 congenital anomaly, 352
 and insurability, 496
 lenses, glucose uptake, *233

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

mucormycosis, 143
neuritis, *153
protein synthesis in lens, and galactose diet, *152
retinal detachment, *74
vascular disease, 503
conjunctival, *149, 375
arteriole-venule ratios, 441-446
venular dilatation, 352, 445
and hypophysectomy, *156
intra-ocular pressure, 441-446
new blood vessel formation, *150, 350
vision impairment, *74, *234
blindness incidence, *428
fluctuating, *231
and rice diet, *152

F

FAMILIAL TENDENCY, *157, *332, *333, 466
and acromegaly, 464
in asymptomatic diabetes, 83
and blood groups, 23
and embryopathy, 373
galactosemia, heterozygosity, *424
glucose tolerance tests, *73
cortisone-, 379-385
prednisone-, 382, 384
and glucosuria in pregnancy, 363
and painless pancreatitis, *425
and prediabetes, 374, 375, 379, 469
in subthreshold diabetes, *78

FAT. See Lipids

FATTY ACIDS, *425
adipose tissue, *338
and epinephrine, *422
and phosphate, *332
release, 261-263, *422
albumin-bound and lipid transport, 261
and cholesterol levels, 146, 499
esterification, 261
half life, 173
fractions, *513
and glucose, 138, 267, *337
conversion to, *421
after hypophysectomy, *332
nonesterified, 499
arteriovenous differences, 117
and lipid metabolism, 138, 173, *513
plasma levels, *337
and barium sulphate, *337
diurnal variations, *237
after foodstuffs, amount and type, *337
and glyceride-glycerol, 261
and growth hormone, 137, 274-276, *333
and phenethylbiguanide, 183, 184
release after insulin, *425
polyunsaturated, 146
sera, in hyperlipemia, *429
synthesis, *422
in diabetic nerve and spinal cord, *335
enzymatic pathways, *156-157

FERRIC CHLORIDE TEST, and salicylates, 416

FERTILITY, and juvenile diabetes, 346, 353

FETUS, *75, *336
See also Abortion; Pregnancy
"Cushingoid," 374, 375
embryopathy, 373-375
and birth weight, 114-117, 293, 346, 352, 398-403, 466-470, 490-493
and insulin degradation, *234
islet tissue, 374, 375
loss, *78, *233
and alloxan, 114-117, 396-403, 490-492
and maternal glucose tolerance, 467-470
previable, *334, 347
resorption, *427
and neonatal deaths, 373, *423
survival, 347, 400-403
See also Pregnancy, management
and vitamin B₁₂, 391

FLUID
balance, in surgery of diabetic, *514
cerebrospinal, in hypoglycemia, *336
extracellular
and body weight, 417
glucagon diabetes, 282
glucose levels, 282
in hyperglycemia, 282, 478

FOLIN-MALMROS TEST, 396

FOODS
See also Diet; Nutrition
habits, and diabetes control, *78
ingestion amount, 179
and glucose tolerance, 288
and salicylate, 417
and urine glucose levels after glucagon, 280-281, 283

FRUCTOKINASE, *426

FRUCTOSE
and adipose tissue insulin response, *421
and glucose tolerance in hunger, 288
and liver enzyme activity, *426
and phenethylbiguanide response, 167, 190-193
tolerance tests, 190
after insulin, *236

G

GALACTOSE CATARACTS, *152

GALACTOSEMIA, *152
heterozygous carrier, *424

GANGRENE
in intestinal mucormycosis, 144
and juvenile diabetes, 350
and small vessel disease, 504

GASTRIC SECRETION

acidity, 15-16, *77
phenethylbiguanide concentration, 164-165, 217

GASTROINTESTINAL TRACT

after chlorpropamide, *514
complications, 348
and absenteeism, 308
submucosal hemorrhage, 95-96
congenital anomalies, and maternal diabetes, 352
corticosteroid catabolism, *333
in diabetic acidosis, 95, 143
and glucagon, 34, 283, *511
glucose absorption, 34, 37, 214, *511
in malabsorption syndrome, 15-18
after methexamide, 26, 28
mucormycosis, 143, 144
and phenethylbiguanide, 207
radiolabeled, 164-165
side effects, *153, 220-224, *237
phlorhizin metabolism inhibition site, *337

GENES

See also Familial tendency; Heredity
developmental, 169
in galactosemia, *424

GLAUCOMA

incidence, *507
secondary, *150

GLIPASOL, *74-75

GLOBIN INSULIN, *424

GLOMERULOSCLEROSIS

See also Kimmelstiel-Wilson syndrome
electron and light microscopy, *150, *425-426
and hemochromatosis, *507
intercapillary, *74
in juvenile diabetes, *339, 350
nodular lesion, *338, 349, *426
in pregnancy, *514
and small vessel disease, *339, 503, 504
and spontaneous diabetes in animals, 488

GLUCAGON

and blood sugar, 32, 53-61, *157, 278-285, 288-289, 357
in amphibians and reptiles, 320-322
diabetogenic action, 288-290
and glucose, 31-37, 282, *429
glycogen deposition after, 33, *156, 280-283, 289, *425, *511
in gout, *150
and growth rate, 280, 282
hyperglycemic action, 36, 264-271
and cortisone, *156, 264, 282
species differences, 53-61
tests after phenethylbiguanide, 196-197, 199
transient, *236, 278, 283
for hypoglycemia, *157, *426
and insulin, 31-37, *157, 248, 282, 357
coma termination, *421
kidney responses, 33, *150, *511

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

SUBJECT INDEX 1960

- liver responses, 31, 33, *156, 288-289, *429
and oxygen consumption, *511
and pancreas, 31-37, 53-62, 68, 265, *236, 265, 278-285, 321-322, *335
prolonged therapy, 278-285
and salivary glands, 34
and urinary excretions, 53-62, *150, 280-283
yeast responses, *511
- GLUCOCORTICOID**
and glucose uptake, 289
and glycogen accumulation, 471
in pregnancy, and carbohydrate metabolism, 142
and temporary diabetes, 374
- GLUCOSAMINE**, and growth hormone, *333
- GLUCOSE**
and 2-aminobiphenyl in colorimetric method, *233
bacterial contamination, 325
blood levels. *See* Blood sugar
cell permeability, 70, 71, 286
in hunger, 288
in cerebrospinal fluid, *336
clearance, in vivo assay methods, 324
consumption, by abdominal mesothelial-cell sarcoma, *79
in extracellular fluids, 282
and fatty acids, 138, *337
metabolism, *332, *421
release from adipose tissue, 261-263, *422
and glucagon, 31-37, 282, *429
and growth hormone, 251-253, 275, 276, 368, 464
homeostasis, first day of life, *233
hyperglycemia in turtles, *423
intestinal absorption, 34, 37, 214, *511
and lactate levels, after phenethylbiguanide, 181, 217
and lipids, 136, 262, *422
synthesis from, *73
and liver, 136
enzyme activity, *154, *426
output, 199, *337, *339, *429
and sulfonylurea-like drugs, *75
metabolism, 51, *74, 171, 198, 219, 261-263, *422, *426
cerebral, *512
and epinephrine, *422
and fasting, *148
and insulin. *See* Insulin
in lens, after galactose, *152
protein sparing effect, *514
oral, in amphibians and reptiles, 320
oxidase test, *76
and ascorbic acid, *428
and pancreatic cells, 31, 35-37
and phenethylbiguanide, 167-169, 170, 181-182, 186, 195-199, 200, 207, 216, 217, 219
phosphorylation, 250-253
protein precursors, 290
radiolabeled, 447-453
renal threshold, *337
and wastage, 288
skin-surface test, 48-52
splanchnic output, 311-317, *339
tolerance tests, 199, 216, 257, 350, *512
abnormal uterine bleeding, *421
in asymptomatic diabetes, *83
after corticotropin, 379
and cortisone, *73, 375-376, 379-385
criteria, 389, 390, 466-467, 469
dietary factors, 19, 37, 387-390
and exercise, *233
and familial tendency, *73, 379-385
and growth hormone, in hypopituitarism, 274
after hydrocortisone, 382-383
and insulin, *236
plasma concentrations, 258
intravenous, *233
double, *512
in malabsorption syndrome, 108
in neoplastic disease, *73, *422
in nondiabetic, 51, 199
nonfermentable reducing substances, *337
and obesity, 374, *512
in painless pancreatitis, *425
and phenethylbiguanide, 195-196, 198, 216, 219
and prediabetes, 373, 375, 379-385
and prednisone, 382, 384
pregnancy, *157, 296, 365, 366, 373, 466, 468
"probable diabetic," 51
in right and left hands, 51
and serum cholesterol concentration, 468, 469
and tolbutamide, 84-88, *234, *236
two-hour postprandial method, *513
and vulvitis, *237
transport, 251-253
tubular reabsorptive capacity, *337
in pregnancy, 363-369
uptake, 250-253
in adipose tissue, 70-71
type differences, *421
after adrenalectomy, *233, 251-253
into amebae during pinocytosis, 70
and vesicle formation, 71
arteriovenous difference, *74, *148, 202, 205, 216, 248, *336, 459, *512
in hunger, 288
and lactate levels, 181-182
by lenses, *233
muscle, 251-253, *336
and phenethylbiguanide, 167, 170, 181-182, 186
and salicylate, 417
splanchnic tissues, *339
urinary excretion. *See* Glycosuria
utilization, *149, 289, 361, *512
and carbon dioxide output, *73
kinetics, mechanical slope reader, *151
- GLUCOSE-6-PHOSPHATASE**
beta, ductular and acinar activity differences, 478-479
hepatic activity, 287
and adrenal cortical extract, 142
- and cortisone, 142, *429
after fructose feeding, *426
after glucose, *234, *426
and insulin, *429
in pregnancy, 142
and phenethylbiguanide, 174-177, 199
- GLUCOSE-1-PHOSPHATE**, *149
- GLUCOSE-6-PHOSPHATE**
heart level, 252
liver content, *514
and insulin, *156
and protein synthesis, *514
- GLUCOSE-6-PHOSPHATE DEHYDROGENASE**
deficiency, 28
after metaxamide, 370
erythrocyte deficiency, and sulfonylurea hepatotoxicity, 370-372
after galactose feeding, *152
and phenformin, 121, 124
- GLUCURONIC ACID**, in pentosuria, *509
- GLUTAMIC ACID**
of brain, and insulin hypoglycemia, *427
and nitrogen balance, 105
- GLUTAMINE**, *427
- GLUTATHIONE**, in Cushing's disease, 368
- GLYCINE**, and cholesterol levels, 146
- GLYCOGEN**
in abdominal mesothelial-cell sarcoma, *79
in ductular epithelium, 474-479
and growth hormone, 471, 475, 476
heart content, 252
and insulin, *333, *336, *339, 474
kidney infiltration, 487
liver levels, *154, 179, 285, *508
glucose-anthrone method, *336
molecular weight in, 478
and tolbutamide, 127, *339
metabolism, *149
in muscle, *333, *336
and phenethylbiguanide, 167, 169, 179, 181, *508
in pancreatic cells, 59-60, 279-285, 474-479
and protein synthesis in *Escherichia coli*, 478
storage diseases, *154, 285, *508
synthesis, 478
in adipose tissue, 325
and uridine diphosphate glucose, *149
- GLYCOSURIA**
and acetazoleamid, *335
in acidosis coma, 293
and adrenocortical damage, 46
after adrenocorticotrophic hormone, 368
Basutoland incidence, *428
in burn-stress pseudodiabetes syndrome, *507

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

SUBJECT INDEX 1960

Clinistix test, and ascorbic acid, *428
and cortisone, 53-62, 394
dietary control, 4, 146
and formaldehyde, 394
after glucagon, 53-62, 278-285
after glucose, 387
forearm tissue uptake, *148
after growth hormone, 38-47, 274
and hepatic gluconeogenesis, 261
and hypercorticalism, 395
and insulin, 195
excess, 328-329
resistance, 248
and insurability, 495
and islet cell carcinoma, *335
and liver function, *510
and myocardial hypertrophy, *513
in pemphigus foliaceus, *335
and phenethylbiguanide, 184, 186-193,
195, 198, 218, 222, 223
of pregnancy, 296, 467-470
and birth weight, 398-399, 490-493
glomerular-tubular relations, 363-
369
and salicylates, 392, 416
and skin glucose reactions, 51
spontaneous diabetes in animals, 486
in steroid diabetes, 394
and stress, *336
after surgery, *512
Tes-Tape test, 472
and tubules, 364
degeneration, *337

GOLGI COMPLEX, 472
after glucagon, 33
after sulfonyleureas, 267

GONADECTOMY, mammary gland
growth after hormones, *424,
*509

GONADOTROPHIN, chorionic, and ges-
tation period, 403

GOUT, glucagon action in, *150

GROWTH HORMONE
and appetite, 39-40, 273
and blood sugar, 39-46, 274, 275, *336
and blood urea nitrogen, 273, *333
and calcium metabolism, 273, *333
and carbohydrate, 273-276, *333
and citrate levels, 274, 275
in diabetes etiology, 353
fat metabolism, 273, 276
and fatty acids, nonesterified, 137,
274-276, *333
and glucosamine, *333
and glucose, 38-47, 274, 276, 368
tissue uptake, 251-253, 275, 276,
368, 464
and glycogen, 471, 475, 476
and growth, 272, 276, *333
and hypoglycemia, 247
idiopathic spontaneous, *426
after hypophysectomy, *237
in hypopituitarism, 272-277, *333
and insulin, 272, 273, 276, 459, 464
resistance, 247
response reversal, 350

in juvenile diabetes, *237, *336, 346
and ketonuria, 274-276
magnesium retention after, 273
in mild diabetes, 274-276
and mucoproteins, *333
nitrogen retention after, 39, 273, *333
and obesity, 39, 46, 273-277
pancreatic effects, 38, 42-46, 63, 265-
266, 472-480
phosphorus retention after, 273, *333
plasma "growth-hormone-like" factor,
*233
and potassium retention, 276, *333
and serum phosphorus levels, 273
sodium retention after, 273
and urine volume, 39-40
and weight, 39-41, 273, *333

GUANIDINES, 170-173, 180
See also specific compounds

H

HAGEDORN-JENSEN TEST, *429

HART, James F., 72

HEART

See also Myocardium
and blood sugar level, 286
bundle branch block, *74
congenital anomalies, 352, *423
glucose uptake, 250-253
phenethylbiguanide clearance, 164-165
and spontaneous diabetes, in dogs, 487
stroke output, *514
weight, after growth hormone, 40-41

HEART DISEASE

and absenteeism, 308
coronary, and emotional factors, *338
and glycosuria, *513
and mortality rates, 141
in thirty-year survivors, 351
and nephropathy, 351, 354
and small vessel disease, 504

HEMOCHROMATOSIS

and glomerulosclerosis, *507
idiopathic, in Ghana, *424

HEMORRHAGE

in diabetic coma, 94-96
after hypoglycemia, *335
in malabsorption syndrome, 108
and mucormycosis, 144
and retinopathy, *74, *150, 349, 350
and growth hormone, *336
and steatorrhea, *425

HEMOSIDEROSIS, *424

HEPARIN

lipemia clearing factor, 137
and sulfated alginic acid in athero-
sclerosis, 291

HEPATECTOMY

and corticosteroid clearance, *333
lipid mobilization after, 135-137

HEPATITIS, *77, 370

HEREDITY

See also Familial tendency
of diabetes, 293, *332, 374, 488
in Chinese hamster, 486, 487, 488
and gestational onset, 296-302
and vascular changes, 349
genetics development, 169
and macromolecule synthesis, 206
mutation, and selection counterpres-
sure, 128
in obese-hyperglycemic syndrome, 63

HORMONES

See also specific substances
adrenocortical, 289
in pregnancy, 355
after gonadectomy, and mammary
gland growth, *424, *509
after hypophysectomy, *424, *509
and lactation, *332
pituitary, and blood sugar, 321
sex, in pregnancy, 350
and embryopathy, 374

HUNGER, 320

"hunger diabetes," 288-290

HYALINE MEMBRANE DISEASE,

*425
in newborn, *338

HYALURONIC ACID, in lipemia, 137

HYDROCORTISONE

clearance, after adrenalectomy, *333
cortisone glucose tolerance after, 382-
383, 384
and fasting blood sugar, 383
and heart glucose uptake, 251-253
and insulin, in diabetes reversal, 350
and lactation after hypophysectomy,
*332
and liver glucose 6-phosphatase, *429
and metabolism in pregnancy, 465
after adrenocorticotropin, 355

17-HYDROXYCORTICOSTEROIDS

and metabolism in pregnancy, 355
plasma levels, and salicylate, 417
urinary excretion, 215
diabetic nephropathy, *428
after phenethylbiguanide, 195-200,
215

HYPERCHOLESTEROLEMIA. See Cholesterol

HYPERGLYCEMIA

in acidosis coma, 293
in burn-stress pseudodiabetes syn-
drome, *507
and carcinoma of pancreas, *152
cortisone, 53-61, *159, 264
nitrogen catabolic effects, *338
in prediabetes, 379-385
and diethyldithiocarbamate, 63
double intravenous test, *512
and embryopathy, 374, 399
and epinephrine, *156, 219, 289
fasting, 293
and glucose tolerance, 383
and glucagon, 53-61, *156, 196-197,
199, *236, 264-271, 278-285,
361

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

- and glucose, 313, *423
and glycogenic changes in beta cells, 474-475, 478
skin-surface test, 48-52
and growth hormone, 63, 265, 274, 275
in "hunger diabetes," 288
and hypophysectomy, 322
and insulin, 260, 282, 321
resistance, 248
withdrawal, 195
juvenile diabetes, *74, 345
and latent diabetes, 293
and liver, 261, *510
and nitrogen excretion, 200, 274, 275
nocturnal, 345
in obese-hyperglycemic syndrome, 65
and oral hypoglycemic agents. *See* specific substances
after pancreatectomy, 265
in pemphigus foliaceus, *335
postoperative, *512
after prednisone, 379
and salicylates, 392-393, 416
species differences, 53-61, 269, 321, *423, 486
"steroid diabetes," 289-290
- HYPERINSULINISM**
in bronchogenic tumor, *513
and growth hormone, 272, 273-277
and hypoglycemia, *336, *513
iatrogenic, 329
- HYPERLIPEMIA**
See also Lipids
and acidosis, 482, 483
in arteriosclerosis, *429, *513
and hepatic gluconeogenesis, 261
vitamin A tolerance test, 295
- HYPERTENSION**, 141, *233
arteriosclerosis, *339
and insurability, 495
in juvenile diabetes, 349, 350
and Rauwolfia alkaloids, *74
rice diet, *152
and small blood vessel disease, 504
- HYPOLYCEMIA**
See also Blood sugar; specific hypoglycemic agents
and acetylsalicylic acid, 200
and amino acids, *75
in abdominal mesothelial-cell sarcoma levels, *79
of brain substances, *427
bronchogenic tumor, *513
and coma, *423
and convulsions, *336, *423
and coronary insufficiency, *334-335
and corticosteroids, *509
and dinitrophenol, 200
emotional and mental disturbances, 329
and encephalopathy, *73
and fibrosarcoma, *511
hemorrhage, *335
and hyperinsulinism, *336, *513
and hypophysectomy, 324-325
and indole-3-acetic acid, *153
in infants, *336, *423, *509, *514
- and insulin substitutes. *See* specific compounds
juvenile diabetes, 345
summer camp operation, *508
leucine sensitive, *336
and liver fibrosarcoma, *422
measurement technics, 324-327
after metabexamide, 26, 28
after pancreatectomy, 321-322
and patient education, 412
and phenylalanine deficiency, *75
and phloridzin, 89
phosphorylcholine, and phosphoryl-ethanolamine, *231
postprandial, 466
in pregnancy, *148, 492
toxic, *423
presenting complaint, *333, *423, 466, 469
shock, after chlorpropamide, 110-113, *423
spontaneous idiopathic, *232, *426, *428, *509, *514
and starvation, amphibians and reptiles, 320
- HYPOKALEMIA**, *74, *338
- HYPOPHYSECTOMY**
and capillary aneurysms, *156
and fatty acids, 137, *332
and glucose, *332
tissue uptake, 251-253
and insulin activity, 246, 346, *424, *510
juvenile diabetes, *237, *336
and mammary glands growth after hormones, *424, *509
and protein metabolism, 346, *510
and retinopathy, *156
species response differences, 321, 322, 346
- HYPOPITUITARISM**, *509
and growth hormone, 273-277, *333
- HYPOTHALAMUS**
and blood sugar, *236
and food intake, 166
and insulin sensitivity, *155
obesities, 263
- I**
- ILETIN**. *See* Insulin
- INDOLE-3-ACETIC ACID**, *153
- INDUSTRY**. *See* Employment
- INFANTS**
congenital anomalies, *232, *338, 351, 373-376, *423, 466
"Cushingoid" appearance, 374
electrocardiogram, *338
electrolyte excretion, *511
erythroblastic, 352
glomerular filtration rate, *511
glucose levels, *234
hypocalcemia, *234, *338
hypoglycemia, *336, *423, *509, *514
leucine-sensitivity, *423
- lungs, hyaline membrane formation, *338
and maternal diabetes, *232, *233, *234, *338, 347, *423
experimental, 114-117, 396-404
and glucose tolerance, 466-470
and insulin, 490-493
mortality, *233, *332, *334, *338, *423, 466
neonatal complications, *76, 114-117, 352, *511
and prenatal care, *233, 347, 350, 376, *423
mental deficiencies, *232
nitrogen excretion, *511
and paternal diabetes, 347, 351, 352, 373
pediatric care, *422
prematurity, *232, *338, 352, *423, *511
renal function, *511
skin, *423
thickness, and fat, *510
water balance, *150, *510
weight loss, 115, *338, *423
- INFECTIONS**, *153
and absenteeism, 307-308
bacteriuria, *151
and diabetic acidosis, *232
fungus, mucormycosis, 143-144
and insulin, 247, *424
resistance, 245, 248
in juvenile diabetes, 348
and latent diabetes, 293, 354
and temporary diabetes, 374
- INSULIN**
absorption, *77, 248
in acromegaly, 245, 247, *514
intra-arterial effects, 459-465
action, 117, 261, 326, *333, 346, *509, *511
effect of excess, 328-330
humoral factors, 245-249
and adenosine triphosphate formation, 179
and adipose tissue, 117, 138, 261, *421
fatty acids esterification, *338
and alpha cells after glucagon and glucose, 31-37
antagonism. *See* Insulin, resistance
antibodies. *See* Antibodies, insulin
assay technics, 254-260, 324-327, 356-362
beef, 254-260
interaction with antiserum, 326
pancreas content, *428
and biguanides, 350
binding, *77-78, *422
and blood citric acid level, *237
and carbohydrates, 138, *157, *234, *236, *333
and carbutamide, *510
and chlorpropamide, *339, 455, *514
clearance, *339
after glucose loading, *337
coma, *421
and duration of disease, 5-7
and cortisone, *338, 350
crystalline, *236, 326, *424, *514

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

SUBJECT INDEX 1960

deficiency in cats, 487
 degradation, 215
 fetal capacity, *234
 in diabetes control, 40-41, *74, 89-93,
 97-99, *148, *234, 324, *339,
 356-362, *424, *429, 460-
 462, 469, *512
 acidosis, *155, *232, 245-248, 293,
 *336
 and diet, *73, *157, *510
See also Diet
 juvenile, 345, 350
 and oral hypoglycemic agents, *75,
 *152, *236, *237, *424,
 *508, *511
See also specific compounds
 patient education, 412
 presurgery, *514
 and vascular lesions, 350, 375
 discovery, *422
 dosage, 329-330
 and glucose-6-phosphate dehydro-
 genase activity, 371
 and glycosuria fluctuations, 328
 and intermittent ketosis, 328
 for short-acting, 4-7
 split-dose schedule, 350
 and unstable diabetes, 328
 electrophoresis, and pH, 326
 and fat metabolism, 375
 and fatty acids, 138, 261
 glass adsorption, gelatin prevention,
 *76
 Globin, *424
 and glucagon, *157, 320, 357, *421,
 *511
 glucagon-free, in turtles, 321
 and glucose, *152, 259, 288, 325, 356-
 362, 447-453
 hepatic output, *337, *339
 phosphorylation, 251-253
 space diffusion estimation, *233
 tissue uptake, *233, 247, 251-253
 transport rate, 253
 and glycogen, *336
 changes in beta cells, 474
 after growth hormone, 40, 247, 272,
 273, 276, *336, *350, 459,
 462, 464
 hindquarter responses, *333
 horse, 254-260
 in hyperlipemia, *151
 hypoglycemia, *73, *157, 328, *421,
 450, 492
 and cerebral amino acids, *427
 leucine sensitive, *336
 and phosphorylcholine, *231
 and phosphorylethanolamine, *231
 after hypophysectomy, 246, *336, 346,
 *424, *510
 inactive, and yeast, *511
 iodinated, *77, *156
 kidney uptake, *156
 and lactic acid production, *148
 and latent diabetes, 293
 lens metabolism, *233
 Lente, 6, *234, *424
 mixtures, *332

-like activity, 89-91, *236, 324, 345,
 346
 and liver, *232
 amino acids uptake, *150
 glucose-6-phosphatase, *429
 phosphorylation, *155, *426
 mammalian, in amphibians or reptiles,
 320, 322
 and mammary glands growth, *232,
 *424
 muscle uptake, *156, 248, *336
 mutton pancreas content, *428
 in nephropathy, 4-5, 6
 and neuropathy, *425
 NPH, 6, 350, 469, 472
 and pancreas hyaline membrane for-
 mation, *338
 and phenethylbiguanide, *153, 168,
 186-193, 216-217, 220-224,
 *237, *424
 combination, 221
 in unstable diabetes, 223
 pinocytosis stimulation, 70-71
 placental metabolism, *335
 plasma levels, *79, 246-248, 256-262,
 *339, 356-362, 463-465, *514
 pork, 254-260
 in pregnancy, *148, 296-298, 301,
 *332, *335, 347, 376, 397,
 403, 469, 490-493
 reaction, 254-260, 325-326, 462
 and duration of disease, 5-7
 psychological problems, 351
 requirements, 6, 248, *333, *335, *338,
 345-346, *422
 fibrosarcoma of liver, *422
 and insurability, 495, 496
 and number of injections, 4-5, 6
 and oral agents, *149, *153, 184-
 185, 186-193, 216, 217, 222,
 224, *231, *237, 350, *424,
 510
See also specific compounds
 after pancreatectomy, 184-185
 and sickness absenteeism, 306-307
 resistance, 245-248, 350, *422, 464-
 465
 after cerebral thrombosis, *236
 diabetic coma, 97-99
 in reptiles, 322
 and steroid therapy, 246-248
 retention after therapy, 254
 in retinopathy, 4
 secretion, 89-93, 259
 in obesity, 68, 374
 stimulation after glucose, 361
 Semilente, 350
 sensitivity, 40, 68, 199, 216, *336, 460
 allergy, 187
 and body weights, *157
 and hypothalamus lesions, *155
 sheep, 254-260, 486
 shock, 320
 and spontaneous diabetes in hamster,
 487-488
 and sulfonyleurea, *231, 350, *424,
 *508
 combined therapy, *234
 derivatives, *231

and tolbutamide, *79, 149, 259, 356-
 362, 455-458
 tolerance, 197, 219
 in neoplastic disease, *73
 Ultralente, 350
 withdrawal, *73, 195, 217
 and fetal mortality, 402
 zinc suspension, 6, *236, 255-260,
 *338, 350, 397, *429, 491
 after dithizone, 32, 35-36

INSULITIS, *427

INTERNATIONAL DIABETES FED- ERATION, 81, 160, 243, 343, 438

INTESTINE. *See* Gastrointestinal tract

IODINE

radiolabeled, *77
 in thyroid function, *337
 serum protein-bound, 468

J

JAUNDICE

after chlorpropamide, *339, *422
 after metahexamide, *337
 after tolbutamide, *507

JOINTS, complications, 348

K

KEMPNER'S RICE DIET, *335

KERATOSIS, 486

KETOACIDOSIS

See also Acidosis, diabetic; Ketosis
 and coma, 293
 in juvenile diabetes, 348
 and staphylococcus pneumonia, 350
 salicylism resemblance, 416

α -KETOGLUTARATE, and growth hor- mone, 274-276

KETONE BODIES

See also Ketoacidosis; Ketonuria
 blood content, 218, 274-276, 293, 316,
 *336, 486
 in diabetes-like states, 289
 after glucose infusion, 316
 formation, 218
 after alloxan, *425
 and phenethylbiguanide, 217
 glucose-anthrone test, *336
 in glycogen disease, *508
 after growth hormone, 274-276
 in liver, *336
 and obesity, 274
 after pancreatectomy, 316
 and phenethylbiguanide, 218
 placental barrier transfer, 402
 Rothera test after glucagon, 280
 and serum insulin activity, *152

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
 July-August, 245-344

March-April, 83-162
 September-October, 345-440

May-June, 163-244
 November-December, 441-522

SUBJECT INDEX 1960

- and spontaneous diabetes in animals, 486, 487
- KETONURIA**
in acidosis coma, 293
and diabetes onset in pregnancy, 296
in glycogen disease, *508
after growth hormone, 274-276
and hypophysectomy, *237, *336
in hypopituitarism, 274, 276
and insulin
 requirements, *336
 resistance, *236, 248
 serum activity, *152
 withdrawal, 195, 217
and obesity, 274
and phenethylbiguanide, 195, 217, 220
and salicylates, 392, 416
- KETOSIS**, *233
and diabetes degrees, 293
and glucose uptake, *74
and hepatic gluconeogenesis, 261
and infection, 187
and insulin, *74, *424
and phenethylbiguanide, *237
during pregnancy, 301
 recurrence, *233
 and renal glucosuria, 368, 369
proneness, 187, 373
after salicylates, 416
and therapy selection, *424
 hypoglycemic agent contraindication, *76, 293
- 17-KETOSTEROIDS**, urinary
and adrenocortical function, 215
and nephropathy, *428
newborn infants, *338
and phenethylbiguanide, 195-200, 215
- KIDNEYS**
See also specific conditions
and blood sugar in hyperglycemia, 286
complications, *338, *426
 and duration of illness, 105, 351
 vascular, 105, 503, *514
congenital anomalies, 352
electron microscopy, *150, *425-426
enzyme activity, *501, *508
fatty degeneration, 121
glucagon effects, 33, *150, *511
 prolonged treatment, 280
glycogen infiltration, 33, 280, 487
in hemochromatosis, *507
insulin uptake, *156
nodular lesions, *338, 349, *426
and phenethylbiguanide, 121, 207, 176
 clearance of radiolabeled, 164-165
 toxic nephrosis, 118-125
in pregnancy, 348, *514
 fatal cortical necrosis, *423
 and glycosuria, 363-369
 perinatal fetal mortality, *233
 and prematurity, *338
and spontaneous diabetes in animals, 486, 487
in thirty-nine-year survivors, 105
in thirty-year survivors, 351
tubules, 33
 glucose reabsorption, *337, 363-369
weight after growth hormone, 41
- KIMMELSTIEL-WILSON SYNDROME**, *150
See also Nephropathy
and duration of illness, 2-3
and glomerular lesions in animals, 485
and small vessel disease, 503
- KREBS CYCLE**, *427
and insulin, *336
and phenethylbiguanide, 200, 217, 218, 219
- ## L
- LACTATE**
blood concentration, 171, 186-193, 196, 216, 219
arteriovenous differences, *512
after glucose infusion, 189, 192
and insulin, 188, *232, *333
metabolism, 193, 198, 217
 cerebral, after eating, *512
 and muscle glycogen, *333, *336
 and phenethylbiguanide, 171, 181, 186-193, 196, 198, 219, 224
 clearance rates, 216
 hepatic uptake, 210, 212-213
production, *148, 167, 169
 and alloxan, *232
 and glucose utilization, 217
transport mechanism, *513
- LACTATE DEHYDROGENASE**
and liver enzyme activity, *426
in pancreatic cells, 479
and phenethylbiguanide, 121, 124
- LACTATION**
in alloxan diabetes, *427
and insulin, *232
and hormone therapy after hypophysectomy, *332
- LACTIC ACID**
blood levels
 after fructose, 190-193
 after sodium lactate, 186, 191, 192
phenethylbiguanide influence, 186-193
production in pregnancy, *148
- LEUCINE**, and hypoglycemia, *336, *509
- LEUCOCYTES**
insulin responsive, 245
 and adrenal steroids, 248
and metahexamide, 28
- LEUKEMIA**, and mucormycosis, 143
- LINOLEIC ACID**
in sera, in arteriosclerosis, *429, *513
vegetable oil content, 146
- LIPID**
See also Hyperlipemia
absorption, 295
anisotropic, and spontaneous diabetes in dogs, 487
and atherosclerosis, *334, *425, *429, *507, *510, *513
- blood levels, *151, 173, *510
 in juvenile diabetes, 481-484
 and microaneurysms, 10-12
 and stress, 137
intake, *337, 415, *510
 and blood sugar level, 37
 in diabetic diets, 145, 350, *425, 499, *511
 optimum, 145-146
and liver, 137, 415, *510
metabolism, *425
 and coronary artery disease, 295
 and growth hormone, 273-277
 and hypoglycemic agents, *510
 obese-hyperglycemic syndrome, 63
 and plasma fatty acids, 173, 261, *337
 in prediabetic stage, *76
 in pregnancy, 466
 and vascular complications, *73
 vitamin A tolerance test, 295
mobilization from adipose tissue, 117
endocrine factors, 135-138
and glucose, 261-263
and liver, 173
phospho-. *See* Phospholipids
serum, *151, *334
 polyen-acid content, *513
storage, 137, 262
 for body energy, *510
and sulfated alginic acid, 291
synthesis from glucose, and carbon dioxide output, *73
transport, 295, *513
vegetable, *337, *510
- LIPOPROTEINS**, *513
and erythrocyte aggregation, *149
in juvenile diabetes, *335, 482-483
- ## LIVER
- and amino acids, *510
 after carbohydrate infusion, *79
 protein uptake, *514
blood flow, 209, 213, *429
 and Eck fistula, *77
and blood sugar level, 286, 313, *510
carbon dioxide production, *425
and carbutamide, 67
and chlorpropamide, *334, 370, 371, *422
cholestasis, 28
cholesterol turnover, *429
cirrhosis, *77, 95, *233, 465
corticosteroid catabolism, *333
in diabetic coma, 95-96
and epinephrine, *155
extract, and growth rate, 214
fatty, *76, 346, *510
 and pituitary extracts, 135
 and spontaneous diabetes in animals, 486, 487
after Glipasol therapy, *75
glucagon effects, 31, 33, *155, *156, 286-288, *425, *429
and glucose, 31, *154, *234
in diabetes-like states, 289, 290
lens uptake, *233
output, 210, 286-291, *337, *339, *429

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

SUBJECT INDEX 1960

inhibition, 207, 361
 after pancreatectomy, 311-317
 postoperative, *512
 glucose-6-phosphatase, *234
 and cortisone, 142
 and glucose-6-phosphate, *156, *514
 glucose-6-phosphate dehydrogenase, in
 erythrocyte deficiency, 371
 glucuronolactone conversion to ascor-
 bic acid, *508
 glycogen, 33, *154, 179, 207, 285, 288,
 289, *339, *429
 and carbon tetrachloride, 126-128
 lysis, 199, *425
 and salicylates, 417
 and insulin, 31, *77, *155, 286-291,
 *234, 326, *337, *339, *510
 ketone bodies, *336
 lactate, 186, 216
 lipogenesis, 136, *425
 and ingested fat, 415
 after metahexamide, 26, 28, 370
 metastatic fibrosarcoma, *422
 in newborn, *423
 after oral sulfonylurea drugs, 371
See also specific compounds
 oxygen consumption, *425
 and phenethylbiguanide, 118-125, 176,
 179, 186, 199, 207, 209, 213,
 216
 clearance of radiolabeled, 164-165
 in pregnancy, *234
 protein, *150, *514
 ribonucleic acid granules, 478
 and starvation, *154
 and tolbutamide, 126-128, *339, 361,
 *507
 urea output, 210
 vascular bypass, *422
 weight, *232, 346, *423, 486
 after growth hormone, 41
 in obese-hyperglycemic mice, 67

LUNG

See also Tuberculosis
 congenital anomalies, 352
 infections, in juvenile survivors, 348
 mucormycosis, 143, 144
 phenethylbiguanide clearance, 164-165

M

MALABSORPTION SYNDROME, 106-
 109
 and diarrhea, 14-19

MALATE DEHYDROGENASE, *426

MALIGNANCY. *See* Cancer

MALNUTRITION. *See* Nutrition

MAMMARY GLANDS

growth stimulation after gonadectomy,
 *424, *509
 lactation, after hypophysectomy, *332
 metabolism, *232, *332, *509

MAMMOTROPIN, *332

MANNOSE, *421

MENINGES, mucormycosis, 143

METAHEXAMIDE, 25-30

and chlorpropamide, 28, 266-267, 455,
 458
 and diabetogenic hormones, *427
 hepatotoxicity, *75, *337, 370
 and glucose-6-phosphate dehydroge-
 nase, 371
 metabolism, 454-458
 patient selection, *75
 solubility, and pH, 456
 and tolbutamide, *149, 266-267, 455-
 458

MONGOLISM, 352

MORTALITY

See also Diabetes mellitus, statistics
 accidental falls, 103
 in Hawaii, *79
 infant, *233, *332, *334, *338, *423,
 466
 of insured diabetics, 139, 497-498, 500
 and juvenile diabetes, 104-105, 351
 maternal, 352
 after myocardial infarction, *426
 perinatal, *76, 299-300, 373, *423,
 469
 in socio-economic groups, 502

MUCORMYCOSIS

cerebral, 143, 144, *339
 cutaneous, 144
 intestinal, 144
 pulmonary, 144
 rhino-, 143

MUSCLE

blood flow, 313
 in hypoglycemia, *73
 and blood sugar level, 311-317
 carbohydrate metabolism, *333
 carbon dioxide, *333
 disorders and absenteeism, 308
 epinephrine effects, 248, 289
 extraocular, paralysis, *509
 and glucose, 289
 transport and phosphorylation, 250-
 253
 uptake, 250-253, 286, *333
 and splanchnic sugar output, 311-
 317
 utilization and salicylates, 417
 glycogen, 181, 207
 stores, and oxygen deficit, 288
 synthesis, *333
 and insulin, *156, 248, *336
 and lactate, *33, *336
 production, 181-182
 motor palsies, *333
 oxygen consumption, *336
 and phenethylbiguanide, 118-125, 174,
 176, 181, 207, 218, 219
 clearance of radiolabeled, 164-165
 pyruvate oxidation, 165

MYOCARDIUM

hypertrophy, idiopathic, *513
 infarction
 and blood flow, *426
 sex ratio, *426

and temporary diabetes, 374
 triolein tolerance curves, *513
 in juvenile diabetes, 349, 350

N

NADISAN. *See* Carbutamide

NATIONAL INSTITUTES OF
 HEALTH, bibliography,
 *236

NELSON-SOMOGYI TESTS, *76, 183,
 472, 482

NEOPLASTIC DISEASE, *73, 141
See also Cancer

NEPHRECTOMY, and splanchnic glu-
 cose output, 313-316

NEPHROPATHY, *338, *428

See also Kidney
 and insurability, 496
 and intravascular erythrocyte aggre-
 gation, *149
 in juvenile diabetes, 1, 349-351, 354
 and hypotensive agents, 353
 and leg lesions, 102
 plasma growth-hormone-like factor,
 *233
 and pregnancy, 347
 and spontaneous diabetes in animals,
 487
 treatment, 1-8

NERVOUS SYSTEM

complications, 141
 extraocular muscles paralysis, *509
 in juvenile survivors, 348
 congenital anomalies, 352
 and diarrhea, 17
 and food intake, 166
 mucormycosis, 143

NETHERLANDS, employment, 129-134

NEUROMYOPATHY, *333

NEUROPATHY

and circulatory reflexes, *514
 duration of illness, 16, 348
 and insulin, *425
 in malabsorption syndrome, 16
 optic, *150
 in uncontrolled diabetes, *153
 prediabetes, *78
 and small vessel disease, 504
 and sulfonylurea therapy, *425

NICOTINIC ACID

and cholesterol levels, 146
 insulin-like activity, 325

NITROGEN

excretion, 198, *338
 after glucagon, *149
 in newborn, *511
 after phenethylbiguanide, 197-198
 metabolism
 after cortisone, *338
 and dextrin, 105

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
 July-August, 245-344

March-April, 83-162
 September-October, 345-440

May-June, 163-244
 November-December, 441-522

SUBJECT INDEX 1960

nonprotein, in burn-stress pseudodiabetes syndrome, 316, *507
retention, 274
after growth hormone, 39-40, 273, *333

5-NUCLEOTIDASE, 174-177

NUTRITION

See also Diet
in amphibians, 320
and chronic disease control, 372
and diabetes incidence, *231
education, 411
and fatty acid release, 138
and glucagon injection effects, 281-282
in reptiles, 320
summer camp operation, *508

O

OBESITY, *333

adrenocorticotrophic hormone secreting tumors, *76
and blood sugar, 219
and cortisone-glucose tolerance tests, 379
and diabetes etiology, *231, *332, 374, 488
and dwarfism, 346
and energy disposition, 219
and growth hormone, 39, 46, 273-277
heredity, *332
-hyperglycemic syndrome, 63-69
in hypopituitarism, 273
and hypothalamus, 166
juvenile diabetes, 346
measurement, 99, 109, 125
and metabolism, 263
newborn infants, *510, *511
transitory complications, 352
and pancreatitis, 487, 488
in prediabetes, 293, 373, 374, 376
in pregnancy, *78, 373, 374
psychogenic factors, 166
and serum magnesium levels, *421
and spontaneous diabetes in dogs, 487
and tolbutamide, *78
weight reduction, and cholesterol levels, 146

OLEIC ACID, *337, *338, *429

OSTEOMALACIA, 15-16, *425

OSTEOMYELITIS, 348

OSTEOPOROSIS, *335

OXYGEN

consumption, 200, 209
and adenosine triphosphate, 179
and dinitrophenol, 170, 171
and diphosphopyridine nucleotide, 171
after glucagon, *511
guanidine inhibition, 170
and insulin, *426
after pancreatectomy, 179, *333
and salicylates, 417

deprivation, 352
and tissue glucose uptake, 251-253
and phenethylbiguanide, 171, 180, 200, 209, 212
saturation, 212

P

P-607. See Chlorpropamide

PALMER, Lester J., 331-332

PALMITINIC ACID, *429

PALMITOLEINIC ACID, *429

PANCREAS

acinar cells, ribonucleic acid granules, 478
adenoma, and hypoglycemia, *336
beef and mutton extracts, *428
carcinoma, *150, *152
and pemphigus foliaceus, *335
cobalt responses, 57, 59-60
"continents" of Langerhans, in off-spring, 375
and cortisone, 264-271
long-term treatment, *156
exocrine cells, 31
fibrosis, *74, 487
glycogenic infiltration, 59-60, 279-285, 474-479
and glucagon, 31-37, 53-62, 68, *236, 265, 278-285, 321-322, *335
Golgi apparatus, 33, 267, 472
and growth hormone, 38, 42-46, 63, 265-266, 472-480
and insulin, 31, *428
crystalline insulin difference, 326
extractability, 346
release, 68, 286
venous concentration, 89-93
islets of Langerhans, 41, *74
in amphibians, 318-322
cell types, 57, *237, *338, *427
alpha, 57, 66, 320, 322
carcinoma, *335
and cortisone, 54-61, 265-270
and glucagon, 31-37, 54-61, 279-285, 322
and glucose, 31-37
and growth hormone, 42-46
after hypoglycemia, prolonged, 178
and insulin, 31-37
lamellar ergastoplasm, 473
metaglucon diabetes, *237, 279, 283
secretory granules, 473
after sulfonylurea derivatives, *231
zinc content, 36
atrophy, 286, 346
beta, *77, *237, 320, *427, 486, 488
and cortisone, 265-270
after dehydroascorbic acid, *77
erythrocyte count as index, *509

after glucagon, 54-61, 279-285
and glucose, 35-37
glycogenic infiltrations, 269, 283-284, 471-480
and growth hormone, 42-46, 269
and hyperadrenocorticism, *76
and insulin, 35-37
lamellar ergastoplasm, 472
metaglucon diabetes, *237, 282-283
mitoses, 266
nuclei and nucleoli, *509
ribonucleic acid, 472
secretory granules, 472-473
species differences, 269, 471-480
after sulfonylurea derivatives, *231
sulfhydryl groups, *77
after carbutamide, 67
after chlorpropamide, 266-270
Golgi image, 33, 267, 472
and hepatitis, *77
and hyperglycemia after glucose, *423
in insulinitis, *427
after metahexamide, 266-270
nuclei, *427, *509
pyknosis, 266
and spontaneous diabetes in animals, 486, 487
after tolbutamide, 266-270
and zinc dithizonate, 32-37
hyalinization, *421
hyperinsulinism, *428
hyperplasia, *237, 283, *338, 345, 352, *426
hypertrophy, 345, 352
insulinogenic agents, *231, 264-271
in obese-hyperglycemic syndrome, 63-69
and prediabetic pregnancy, 374-376
in reptiles, 319-322
tumors, *335, *428, *514
and obesity, 63-69, 374, 487, 488
and phenethylbiguanide, 118-125, 176, 207
tissue transplant, 351

PANCREATECTOMY

and alloxan diabetic pregnancy, 396-404
in amphibians, 321
carbohydrate metabolism after, and insulin, *333
and glucose uptake, 313-315
and lipid metabolism, *429
and phenethylbiguanide, 183, 184
and plasma ketone bodies, 316
in reptiles, 321
and splanchnic sugar output, 311-317
in spontaneous hypoglycemia, *426
in turtles, 321

PANCREATITIS

painless, *425
and prediabetes, 375
and spontaneous diabetes in animals, 486, 487, 488

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

SUBJECT INDEX 1960

PANHYPOPITUITARISM, *336

PARALYSIS, extraocular muscles, *509

PARATHYROID GLANDS, fatty infiltration, 487

PASTEUR EFFECT, 200, 207

PEBG. *See* Phenethylbiguanide

PEMPHIGUS FOLIACEUS, *335

PEMPHIGUS VULGARIS, *234

PENTOSE

See also specific

distribution space, 167

and dinitrophenol, 168

and insulin, 168

and phenethylbiguanide, 167, 168

metabolism, *514

glucuronic acid block, *509

PERCHLORIC ACID, *336

PHENETHYLBIGUANIDE

action mechanism, 170-173, 217, 219-221

and adrenal function, 194-200, 215, 219

and arylsulfonyleurea drugs, 222-224

and blood sugar, 118-125, 174-177, 180, 202-206, 218-219, *508, *511

dosage effects, 218-219

after fructose, 190-193

and after insulin, 200

with insulin, 221

species differences, 204

in uncontrolled diabetes, 198

in brittle diabetes, 220-221, 224

and chloride excretion, 195-200

and citric acid metabolism, 186-193

and creatinine excretion, 195

and dinitrophenol, 170, 171

and electron transport, 171

and enzyme systems, 180, 199

genetic significance, 182

and glucagon tests, 196-197

and glucose, 195, 199, 216

distribution, 167-169

tolerance test, 196-197, 219

uptake, 170, 181-182, 186

utilization, 182, 184, 200, 202-206, 207

and glycogen, 170, 207

in fasted animals, 179

and 17-hydroxide excretion, 195-200

hypoglycemia, 171, 195, 207, 218, 221, 223, 492

and insulin, 219

combined therapy, *153, 221

requirements, *153, 186-193, 216-217, 220-224, *237, *424, *428

-sparing action, 224

tolerance test, 197, 219

and insurability, 496

in juvenile diabetes, 220-222, *237, 424

and growth, 223

and ketosis, *237

Krebs cycle effects, 217, 218, 219

and lability control, 224

and lactate, 170, 181-182, 198, 200, 212-213, 216, 222

and lactic acid, 186-193

and liver metabolism, 207-214

metabolic effects, 171, 183-185, 186, 194-201, 207-214, 215-219

and dosages, 181

in nondiabetic, 202-206, 218-219

and nitrogen excretion, 195-200

and oxygen uptake, 171, 179, 180, 186

patient selection, *156, 187, 220, *424

and duration of illness, 195, 222-224

pKa, 164

and plasma fatty acids, 184

and potassium excretion, 195-200

and pyruvate, 197-200, 210, 212-213

and pyruvic acid, 186-193

radiolabeled, 163-166, 181

renal lesions, 118-125

for seizures in child, 223, 224

side effects, 183, 184-185, 200, 220-221, 223-224, *237, *428, *508

and sodium excretion, 195-200

and sulfonyleureas, *76, 222, 224

in surgery, 179

symposium, 163-227

panel discussion, 178-182, 215-219

special problems, 221-222

summary, 225-227

and synthalin, 178

and tolbutamides, 221, 223

secondary failure, *149

toxicity, 178

and unstable diabetes, *156, *508

N- β -PHENETHYLFORMAMIDINYLMINOUREA. *See* Phenethylbiguanide

PHENFORMIN. *See* Phenethylbiguanide

PHENYLKETONURIA, *75

PHEOCHROMOCYTOMA, 289

PHLORHIZIN

and glucose absorption, *337

pretreatment, and insulin secretion, 89, 93

PHOSPHATASE

acid, *335

and blood sugar, 174-177

alkaline, 174-177

and chlorpropamide, *334, *422

and glucose-6-phosphate dehydrogenase activity, 371

in malabsorption syndrome, 15-16

after oral sulfonyleureas, 371

PHOSPHATE

and adipose tissue fatty acid uptake, *332

uptake, and phenethylbiguanide, 167, 169, 180

PHOSPHOETHYLANOLAMINE, *427

PHOSPHOGLUCONATE DEHYDROGENASE, *152, *426

PHOSPHOLIPIDS

of chylomicrons, radiolabeled, 173

and growth hormone, *333

in juvenile diabetes, 483

linoleic acid, *513

and lipid mobilizer, 136

orthophosphate uptake, *231

polyen-acid content, *513

PHOSPHORUS

and diarrhea in malabsorption syndrome, 15-16

homeostasis, in neonate, *234

retention, after growth hormone, 273, *333

PHOSPHORYLATION

capacity, and age, 170

liver, *154, *155

in muscle, 250-253

and phenethylbiguanide, 179-180, 199

PHOSPHORYLCHOLINE, *231

PHOSPHORYLETHANOLAMINE, *231

PINOCYTOSIS, and insulin, 70-71

PITUITARY GLAND

acidophil regression, *155

function, and diabetes therapy, *508

and glucose phosphorylation, 251-253

gonadotrophic cell atrophy, *155

infarction, and diabetes amelioration, *509

and lipid mobilization, 135-138

tumor, *76

and retinopathy, *153

weight after growth hormone, 41

PLACENTA

insulin degradation, *234

and maternal diabetes, 352

embryopathy, 374

PLASMA

amino acids after carbohydrate, *79, 183-184

atherogenesis factors, *334

citrate levels, 274

"clearing factor inhibitor," 135

cortisol level, 465

after adrenocorticotrophic hormone in pregnancy, 355

binding, 493

factor, in body growth retardation, *233

fatty acids, 136, 137, 173

diurnal variations, *237

fasting, *237

and foodstuffs, *337

and glucagon, 183

and glyceride-glycerol as glucose as source, 261

after growth hormone, 274, 275

and phenethylbiguanide, 183, 184

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

SUBJECT INDEX 1960

postprandial, 275
and tolbutamide, 184
17-hydroxycorticosteroid levels, *429
in salicylate intoxication, 417
and insulin, in acromegaly, 246-248,
*429, 463-465, *514
in early maturity-onset diabetes,
254-260
after glucagon, *339, 357
immuno-assay method, 259
inhibitor, 246, 248
after tolbutamide, *79, 259, 356-
362
lipids, and lipid mobilization, 136, 137
membranes of adipose cells, invagina-
tion, 70
metahexamide clearance, *76
nonprotein nitrogen, *507
after pancreatectomy, 316

POLYDIPSIA, 280, 296

POLYEN-ACIDS, *513
See also Fatty acids, nonesterified

POLYSACCHARIDES
and diet, 317
in nephropathy, *428
sulfated, and atherosclerosis, 291

POLYURIA
and diabetes onset in pregnancy, 296
and growth hormone, 39-40

PORPHYRIA CUTANEA TARDA, *512

POTASSIUM
and acidosis, *155, *232
homeostasis, in infants, *234
metabolism, and phenethylbiguanide,
195-200
retention, and growth hormone, *333

PREDNISOLONE, in malabsorption syn-
drome, 16

**PREDNISONE-GLUCOSE TOLER-
ANCE TEST**, 379-385

PREGNANCY, diabetic
See also Abortion; Fetus; Infants
and acidosis, 296
and adrenocortical hormones, 355, 493
alloxan, 114, 117, 396-404, *427, 490-
493
amniotic fluid production, 347
and birth injury, *233, *334
and blood sugar, *157, 296, 490-493
and body water of newborn, *510
carbohydrate metabolism, 142, *148,
*157, *234, 296
coma, 301, *423
congenital malformations, *232, *338,
351, 352, 373, 375, 376, *423,
466
and cortisol, 355
half life, 465
plasma binding, 493
delivery, *423
cesarean section, *332, *338, 398

spontaneous, 397-400, 490
termination date, *233, *423
diabetogenicity, *148, *233, *234, 375
embryopathy, 114-117, 293, 352, 373-
375, 398-403, 466-470, 490-
493
and fetus. *See* Fetus
and gestation period, 398-403, 490
and gigantism, in offspring, 375
glomerular filtration rate, 365
postpartum, 366-367
glucose
metabolism, 466-470
tolerance, 361, 363, 364, 365, 366,
373
cortisone-, 376
tubular reabsorption, 365-366
glucose-6-phosphatase activity, 142
and glycosuria, 364-369
benign, *78
hypoglycemia symptoms, 467
and insulin, *157, *234, 296-298, 301,
*332, *335, 376, 397, 403,
469, 490-493
and lactic acid production, *148
-like activity in serum, 468-470
placental metabolism, *335
plasma concentration, 361
requirements, *335
in juvenile survivors, 346-355
latent, 296
and malformation. *See* Congenital
anomalies
management, *233, 347-353, 373, 376,
*422, *423, 490-493
diet, 347, 469
and history, 466-470
prophylaxis, *233, *335, 376
transitory cases, 297, 301
and maternal age, *78, 296-297, 301-
302, 347, 361, 363, 365, 467-
468
neonatal death, 373, *423
and obesity, *78, 373, 374
of newborn, *510
onset during, and prognosis, 296-302
and parity, 296-297, 300-302, *332,
467
perinatal mortality, *76, 299-300, 373,
*423, 469
prediabetic state, *78, *334, 363, 364,
373-378, *423, 466-470
prematurity, *232, *338, 352, *423,
*511
prenatal care, *233, 347, 350, 376,
*423
and renal function, 347, 350, *511,
*514
and retinopathy, 347
and spontaneous diabetes in animals,
486
stillbirths, *232, *233, 376, 397, 400,
466, 492
and prediabetes, 373, *334, *423
tetrahydrocortisol, half life, 465
and thyrotoxicosis, *335, *336
toxemia, *423
vascular lesions, 347, 350, 353-354
vitamin B₁₂ deficiency, 391

PROGESTERONE
and mammary gland growth, *509
in prenatal care, 347

PROTEIN
in aqueous solutions, substitution
method, *77
body stores, glucose homeostasis, 289
and carbohydrate, *151
metabolism in beta cells, 478
sparing action, 214
dietary, 317, 469
and cholesterol levels, *73
prescription, 145, 350, *425, *511
and fatty acids, *337
transport, 173
gluconeogenesis, and phenethylbiguan-
ide, *156, 200
and glycogen synthesis and storage,
478
in malabsorption syndrome, 15-16
seromucoid, 317
and serum, *151
fractions, in juvenile diabetes, 482-
483
and glycoprotein, 317
and intravascular erythrocyte aggre-
gation, *149
synthesis
and pancreatic tissue, 478, 487
pyridine nucleotides, *514
and ribonucleic acid granules, 478

PROTEINURIA, *74
in juvenile diabetes, 349, 350
and nephropathy, 3-7

PROTHROMBIN
in malabsorption syndrome, 15-16, 108
and painless pancreatitis, *425
synthesis, and vitamin K, 108
time, 108
and glucose-6-phosphate dehydro-
genase activity, 371
after oral sulfonylurea drugs, 371

PYELONEPHRITIS, *74, 350

PYRIDINE NUCLEOTIDES
lipogenesis stimulation, *335
and protein synthesis, *514

PYRUVATE
blood levels, 219
arteriovenous differences, 209-213,
*512, *513
and growth hormone, 274
metabolism, 198-199, 200
cerebral, after eating, *512
and phenethylbiguanide, 171, 181,
186-193, 197-200, 210, 212-
213, 216
tolerance test, 197
transport mechanism for, *153

PYRUVIC ACID and phenethylbiguan-
ide, 186-193

R

RADIOCHROMATOGRAPHY, *232,
255

RASTINON. *See* Tolbutamide

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

SUBJECT INDEX 1960

RAUWOLFIA ALKALOIDS, *74

RETINOPATHY, *74, *334

- and diet, 4-7, *152
- and duration of illness, 2-7, 16, *150
- after hypophysectomy, *156
- and intravascular erythrocyte aggregation, *149
- in juvenile diabetes, 349, 350, 353
- remissions, *335
- in malabsorption syndrome, 17
- and pituitary tumor, *153
- and pregnancy, 347
- renal function, *339
- Scott's degree classification, 3-4
- and small vessels disease, 9-13, 102, 149, 441-446, 503
- treatment, 1-8

RHINOMUCORMYCOSIS, 143

d-RIBOSE, *514

RIBULOSE 5-PHOSPHATE, *152

RICE DIET, *152, *335

RP 2259. *See* Glipasol

S

SALICYLATES

- and carbohydrate metabolism, 416-418
- and hyperglycemia, 392-393

SCOTT'S RETINOPATHY CLASSIFICATION, 3-4

SECRETIN

- in malabsorption syndrome, 15-16
- in painless pancreatitis, *425

SERINE, *427

SEROTONIN, *335

SERUM

- albumin, 173, 317, 482-483
- fatty acid binding, 173
- bilirubin, after sulfonyleureas, 371
- carbon dioxide, in ketosis, 293
- cholesterol, *333
- and atherosclerosis, 146, *507
- and glucose tolerance, 466-470
- protein intake, *73
- water deprivation, *231
- chlorpropamide, persistence, 112
- citrate levels, in obesity, 274-275
- electrolytes, *429
- in burn-stress pseudodiabetes syndrome, *507
- after growth hormone, *333
- in surgery of diabetic, *514
- fatty acids, *73, *333, *429
- insulin, *152
- binding, *77, *152, 254-260, 467, 468
- like activity, 466
- assay, 326, 467, 468-470
- and diabetic coma, 97-99
- in hypoglycemia, *509
- and streptokinase, 325
- lipids, *73, *149, *333, *513

and acidosis, 482

in arteriosclerosis, *429

fractions, 317

polyen-acids content, *513

juvenile diabetes, 481-484

magnesium levels, *421

phosphorus levels, *273

in infants, *234

polysaccharides, in nephropathy, *428

proteins, 482-484

and carbohydrate, *151, 317

and microcirculation alterations, *149

in pinocytosis, 71

salicylate levels, and poisoning, 416

vitamin B₁₂ levels and sorbitol, 391

SHOCK

in diabetic acidosis, *156

insulin, in amphibians and reptiles, 320

after myocardial infarction, *426

SITOSTEROL, 146

SKIN

amino acid uptake, 478

infections, *423

in juvenile diabetes, 348

in newborn infants, *423

thickness, and fat, *510

rash, after metahexamide, 28

and small vessel disease, 349, 504

and spontaneous diabetes in animals, 486

surface-glucose test, 48-52

ulceration, *339

second leg involvement, 100-103

SODIUM

deficiency, *234

and diabetic acidosis, *155

dietary intake, 195

in juvenile diabetes, 353

in prenatal care, 347

and urinary aldosterone excretion, 393

excretion, and phenethylbiguanide, 195-196, 198, 214

retention, 347

after cortisone, *338

after growth hormone, 273

thiosulfate, clearance after glucose, *337

SOMATOTROPIN

and insulin tolerance, *155

and lactation, *332

SOMOGYI TEST, *76, *183, *472, 483

Nelson modification, *76, 183, 482

SORBITOL

as glucose substitute, 499

and vitamin B₁₂ absorption, 391

SPLEEN

lipids, and sulfated alginic acid, 291

and phenethylbiguanide, 207

clearance of radiolabeled, 164-165

and spontaneous diabetes in animals, 487

weight, after growth hormone, 41

SPRUE, 16, 107

STARVATION

See also Hunger

and adipose tissue fatty acids, 138

and glucose tolerance, 386

and phenethylbiguanide, 179

STEARINIC ACID, *429

STEATORRHEA

and bone pain, 15-18, *425

and cancer of pancreas, *510

malabsorption syndrome, 15-18

and corticosteroid therapy, 14

and painless pancreatitis, *425

and spontaneous diabetes in animals, 48

STEROIDS

See also specific substances

adrenocortical

and glucose uptake, 247

and reabsorption, 368

and insulin resistance, 246-248

clearance after adrenalectomy, *333

diabetes induction, 288-290

and chlorpropamide, *427

and stress, 394-395

and tolbutamide, *427

Walker carcinoma implantation, *336

for hypoglycemia, *336

spontaneous idiopathic, *426

and mammary gland growth, *424, *509

urinary excretion after phenethylbiguanide, 195-197, 200, 215

STREPTOKINASE, 325

STRESS

and blood coagulation, *338

burn, pseudodiabetes syndrome, *507

and fat metabolism, *338

and glycosuria, *336, *337, 395

and hypercorticism, 395

neuromuscular, 395

and formaldehyde, 394

surgical. *See* Surgery

STRONTIUM LACTATE, *335

SUCCINATE

conversion to fumarate, 176

and oxygen consumption, *511

SUCCINIC DEHYDROGENASE, after

phenethylbiguanide, 121,

124, 174-177

SUCROSE

intake, and nitrogen balance, 105

starch replacement, and growth rate, 214

and water accumulation, 177

SULFANILYL-BUTYLCARBAMIDE.

See Carbutamide

SULFOBROMOPHTHALEIN

clearance, and hepatic vascular bypass, *422

retention after chlorpropamide, *422

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

SULFONAMIDES. *See* Sulfonylureas

SULFONYLUREAS, *148

See also specific compounds

acetylation, *234

blood sugar, *76, *427

and carbohydrate metabolism, *508

and cortisone effects, *427

and glucose production, *75

after growth hormone, *427

hepatotoxicity, 3

and erythrocyte glucose-6-phosphate dehydrogenase deficiency, 370-372

and insulin, *73, *153

combined therapy, *234, 350

mechanism of action, *231, *508

and neuropathy, *425

and pancreatic islets, *231, 264-271

and phenethylbiguanides, *76, 222, 224

prophylaxis in prediabetes, 376

selection of patients for, *235, 345, 371, *424, *425

and thyroid function, *337

SULPHONILYL-BUTYL CARBAMIDE.

See Carbutamide

SURGERY

genitourinary, *153

and glycosuria suppression, 395

and insulin therapy, *514

and latent diabetes, 293

and lipid mobilization, 137

and phenethylbiguanide effects, 221

postoperative measures, *152, *514

preoperative care, *514

SYNTHALIN, toxicity, 121, 178

T

TEMPERATURE

and metabolism in amphibians and reptiles, 320, 321

and plasma insulin concentrations, 256

TES-TAPE TEST, *472

TESTOSTERONE, and mammary gland

growth, *424

TESTOSTERONE ENANTHATE, *335

THREONINE, and growth rate, 214

THROMBOSIS

cerebral, and insulin resistance, *236

in mucormycosis, 143

renal vein of newborn, 352

THYROID GLAND

and glucose, 466

renal tubular reabsorption, 368

hormones, 368, *509

See also Thyroxine

and phenethylbiguanide, 219

in pregnancy, *335, 466

and sulfonylureas, *337

and temporary diabetes, 374

THYROXINE

and cholesterol levels, 146

globulin binding after phenethylbiguanide, 215

and growth, *509

of mammary glands, *424, *509

and insulin, in diabetes reversal, 350

and thyrotoxicosis in pregnancy, *336

TISSUE

acinar, cell mitosis, 266-268

adipose, 164-165, 286, 289, 324, *421

fatty acids, 117, 138, 261-263

and glucose, *73, *76, 138, 205

consumption, 70, 286

after epinephrine, 289, *422

and glyceride-glycerol formation, 261, 262, *422

and hyperadrenocorticism, *76

lipid storage, 99

and release, 117, 261-263

and obesity, *76

See also Obesity

palmitate metabolism, *332

epididymal, *421

phenethylbiguanide clearance, 164-165

and insulin, *73, 117, 138, 248, 260, 261, *421

in acromegaly, 462-465

-like activity, 324

and pinocytosis, 70

See also Insulin

TOLBUTAMIDE, *334

absorption rates, 455-458

in adult diabetes, *75, *78, *339, *508

in alloxan subdiabetes, *236

and blood citric acid, *237

and blood sugar, *79, 83-88, 266, 356-362, *427

and carbohydrate metabolism, *234

in asymptomatic, 83-88

and carbon tetrachloride intoxication, 126-128

and carbutamide, 455-458

and chlorpropamide, *76, *149, *334, *339, 455-458, *426, *508, *514

and diabetogenic hormones, *427

and duration of illness, *338

failure, *76

secondary, *148, *149, *423

glucose tolerance, 84, *234

hypoglycemic effect, *75, *153, *334

after pancreatectomy, *427

potencies, 454-458

and insulin, *79, *149, *237, 455-458, *511

plasma levels, 259, 256-362

and insurability, 496

and liver, 126-128

glycogen, *339

and metahexamide efficiency, 28, 455-458

patient selection, 126-128, 293, *337, *424, *511

and ketosis, *76

persistence of response, *76

and phenethylbiguanide, *149, 221

addition, 223

and plasma fatty acids, 183

and porphyria, *512

in prediabetes, 293

sensitivity, 221, *507

solubility, and pH, 456

and thyroid function, *337

toxicity, *153, *511

and weight gain, *337

TRANSAMINASES, hepatic activity, *426

TRIOLEIN

absorption, *425

tolerance curves, *513

TRIPHOSPHOPYRIDINE NUCLEOTIDE

in galactose cataract, *152

in protein synthesis, *514

TRYPTOPHAN

in alpha cells, and glucagon, 33

in pancreas carcinoma, *335

and growth rate, 214

TUBERCULOSIS

in juvenile survivors, 348

and nephropathy, 3

and nutritional level, 372

and phenethylbiguanide therapy, 224

in unstable diabetes, 223

U

ULCERATIONS

and fate of second leg, 100

and spontaneous diabetes in animals, 486, 487

and tetanus, *339

UREA NITROGEN, excretion

and chlorpropamide, *334

after cortisone, *338

after glucagon, *149

URIC ACID, excretion, *149-150

URINE

calcium excretion, 273

citrate excretion, 274, 275

concentration, *514

ascorbic acid, and glucose-oxidase

test, *428

after chlorpropamide, *334

after cortisone, 53-62, *338

after glucagon, 53-62, *149, 280-283

in gout, *150

after growth hormone, 39-46, 275, *336

and nephropathy, 3, *428

and phenethylbiguanide, 181, 183,

186-193, 195-200, 215-217

radioactivity, 164-165

in pregnancy, 355, 363, 469, 492

after salicylates, 392, 416

glycogenic corticoids excretion, 355

hydroxide excretion, 195-200

17-hydroxycorticosteroids, 195-200,

215, *428

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82

July-August, 245-344

March-April, 83-162

September-October, 345-440

May-June, 163-244

November-December, 441-522

SUBJECT INDEX 1960

ketones. *See* Ketonuria
 17-ketosteroids, 195-200, 215, *428
 in newborn, *338
 lactic acid excretion, 186-193
 nitrogen excretion, 195, 198, 275
 pentose metabolic products, *514
 potassium excretion, 195-200, 275
 pyruvic acid excretion, 186-193
 sodium excretion, 195-200, 275
 specific gravity, in burn-stress, *507
 sugar content, 183, 216-217, 363, 396
 in cerebrovascular accidents, 49
 after cortisone, 53-61
 diurnal variations, 328
 free, and diabetes, *231
 after glucagon, 53-62, 280-283
 and growth hormone, 39-46
 after insulin, 40-41, 472
 and skin test, 49
 in subdiabetic rats, 114
 in vulvitis, *237
 See also Glycosuria
 tests, 51
 by blind, *428
 and diet, 469
 reliance, 293
 routine, *237
 Somogyi method, 396
 urea nitrogen excretion, *149, *334,
 *338
 uric acid excretion, *150
 volume, 39-40, 177, *507
 zinc excretion, *74

V

VALINE, 214

VASCULAR DISEASE. *See* Blood vessels

VITAMINS, *511

antibiotic mixture, and growth, 214
 A, tolerance test
 in diarrhea, 15, 16, 107
 and fat metabolism, 295
 in malabsorption syndrome, 15, 16,
 106-108

B₁₂, 214

absorption, and sorbitol, 391
 in nephropathy, *428

K, 108

and phenethylbiguanide hypoglycemia, 179

VULVITIS, and glucose tolerance test,
 *237

W

WATER BALANCE

after dextrin, 177
 in diabetic acidosis, *155
 in newborn, *150, *511
 and phenethylbiguanide, 168
 and serum cholesterol, *231
 after sucrose, 177

WEIGHT

See also Obesity
 acetylsalicylic acid, 393
 after carbutamide, in obese-hyperglycemic mice, 67
 and diabetes control, *74, 219, *231,
 *337, 497

and diet, 219, 387-388, *510
 for reduction, 274, *424
 repletion, 317
 gain, and arylsulfonyleureas, *337
 and growth hormone, 39-46, 273
 and insulin sensitivity, *157
 and insurability, 495, 497
 loss, 387-388
 in animal, *232, 486
 and diabetes onset in pregnancy,
 296
 newborn infants, 115, *338, *423
 and painless pancreatitis, *425
 and salicylates, 417
 in nephropathy, 5
 and Rauwolfia alkaloids, *74
 in retinopathy, 5

WILDER, Russell Morse, Sr., 419-420

X

XANTHOMATOSIS, *510
 and sulfated alginic acid, 291

XYLOSE, 168, *514
 in steatorrhea, *425

Z

ZINC

in pancreatic cells, reactivity, 33-36
 urinary excretion, *74

ZOJA, Luigi, 229

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
 July-August, 245-344

March-April, 83-162
 September-October, 345-440

May-June, 163-244
 November-December, 441-522

AUTHOR INDEX 1960

In this index are the names of authors of articles which have appeared in **DIABETES** and those whose articles have been abstracted in the Journal during 1960. Entries marked with an asterisk (*) indicate authors of material which appeared in the **ABSTRACTS** only. For subject index see page 1.

A

Abraham, S., *332
Adams, J., *421
Adams, Reuben, *337
Adlersberg, David, *73
Albanese, A. A., *73
Alert, Harold A., *76
Allwood, M. J., *73
Almasy, F., *74
Alp, Haluk, *425
Alterman, Seymour L., *507
Altschul, Rudolph, *231
Andersen, Jørgen, 20-24
Annechiarico, F., *233
Ansell, G. B., *231
Appelman, David H., *73
Arai, Y., *149
Arduino, Francisco, *421
Arieff, Alex J., *421
Armstrong, John R., *507
Arney, Glen K., *507
Ashmore, James, *339
Ashworth, M. A., *234

B

Baird, Joyce D., *425
Baird, Robert, *334, *423
Baird, R. William, *507
Baker, Roger D., 143-145
Baldwin, Robert S., 220-221, *332
Ball, Eric G., 70-71, *73, *76, *421
Bally, Peter R., *332
Balodimos, Marios C., *421
Bänder, A., *231
Banowitch, Morris M., *508
Barnes, Robert H., 25-30, *340
Barnett, Russell J., 70-71
Barrow, J. Gordon, *334
Barta, L., *332
Bashir, Ahmad, *428
Bastenie, P. A., *233
Beardwood, Joseph T., Jr., 228
Beaser, Samuel B., 222-224
Beatty, Clarissa H., *333
Beaven, Donald W., *148, *231
Bech, K., 441-446
Beck, John C., *333
Becker, Donald, *507
Beckett, A. Gordon, *421
Beckman, Martin, *512
Bedrossian, Robert H., *231
Beigelman, Paul M., 97-99
Bell, E. T., *421

Bellet, Samuel, *513
Benjamin, Fred, *421
Bergen, Stanley S., Jr., 183-185, 215-219, 286-291
Bergren, William R., *424
Berkmen, Rasim, *334
Berson, Solomon A., 254-260, 356-362, *422
Berstein, Donald E., *422
Bessman, Samuel P., *333
Best, C. H., *232, 278-285, *422
Biegler, R., *428, *513
Birch, Herbert W., *237
Bischoff, A., *333
Bishop, Jonathan S., *73
Björkstén, G., *156
Black, Herman, 356-362
Black, Melvin B., *339
Blank, Heinz, *513
Bloom, Arnold, *73, *75, *231
Bloxam, Hazel R., *428
Bocek, Rose Mary, *333
Böck, F., *427
Bogdonoff, M. D., *425
Bogoch, A., *73, *74
Böhle, E., *428, *513
Bojesen, Ejgil, *333
Bolinger, Robert, 178-182
Bonanno, Charles A., *510
Bookman, John J., 14-19
Boshell, Buris R., *512
Bousvaros, G. A., *422
Bouton, Malcolm A., *507
Bradley, T. R., *232
Bradshaw, Maire, 118-125
Brandman, Otto, *333
Braunstein, John R., *78
Bretthauer, Roger K., *424
Briggs, J. H., *336
Broberger, O., *232
Bronstein, Howard D., *232
Brown, George, *422
Brown, Josiah, 207-214
Bryan, Henry G., *157
Buckman, Lewis T., *148
Burnham, DeWitt K., *339
Burt, Richard L., *148
Butler, Frank K., 386-391
Butterfield, W. J. H., *74, *148, *336

C

Cady, P., *332
Cahill, George F., Jr., 261-263, *332, *422

Caldwell, Bettye M., *336
Calenda, Daniel G., *509
Canary, John J., *78, *148, *423
Castillo, Cesar A., *512
Cattell, R. B., *340
Chaikoff, I. L., *332, *426
Chain, E. B., *74, *232
Chalmers, Donald W., 167-169, 178-182
Chalmers, Thomas C., *77
Chalmers, T. M., *235
Champion, R. H., *512
Chatterjee, G. C., *507
Chatterjee, I. B., *507
Christophe, Jean, 63-69
Claye, Andrew M., *422
Coates, John Robert, *423
Cohen, Alan S., *74, *232
Collens, William S., *508
Colwell, Arthur R., Jr., *148
Colwell, Arthur R., Sr., 405-415, 503-505
Combes, Burton, *337
Conard, V., *233
Conn, Jerome W., 83-88, 194-201
Constam, G. R., *74
Contopoulos, A. N., *427
Coodin, Fischel J., *426, *509
Cooper, Gerald R., *334
Cooper, Octavia, *73, *76, *421
Cooperstein, S. J., *233
Cornblath, Marvin, *423
Coronado, Marguerite, *78
Corrêa, P. Riet, *423
Cortesi, Joseph B., *507
Crabbe, Jean, *78
Craig, James W., 186-193, 215-219
Craig, W. S., *422
Crawford, James, *421
Crawford, John D., *75
Crawford, S., *75
Creutzfeldt, W., *339
Creveld, S. van, *508
Crompton, Charles W., *512
Crowley, Mory F., *75

D

Da Cruz Ferreira, Francisco, *421
Daily, Ray K., *507
D'Alonzo, C. A., 303-310
Danforth, Nicholas, 170-173
Daniels, Robert S., *148
Danowski, Thaddeus S., 215-219, 292-295, 406-407

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

Dardin, Vincent J., *334
 Davis, T. W., *73, *74
 Dekaban, Anatole S., *232, *334, *423
 Delahunt, Charles S., *334
 DeLawter, DeWitt E., *78, *148, *423
 de Roeth, Andrew, Jr., *334
 Dillon, John A., *509
 Ditzel, Jörn, *149
 Dobson, Harold L., 220-221, *507, *508
 Dodge, Philip R., *75
 Dodge, Warren F., *508
 Dodu, Silas R. A., *424
 Dolger, Henry, 222-224, *334
 Donnell, George N., *424
 Donovan, B. T., *424
 Doorenbos, H., 194-201
 Drey, Norman W., *75
 Drischel, H., 311-317
 Duncan, Garfield G., *424
 Duncan, Leslie J. P., *425

E

Egeli, Ekrem Serif, *334, *425
 Egense, Johan, *333
 Eisler, Lisbeth, *73
 Eliasson, Sven G., *335
 Ellenberg, Max, 14-19, *425
 Elrick, Harold, *149, *151
 Elwood, J. C., *425
 Emerson, Kendall, Jr., *78
 Engbring, N. H., *337
 Engelhardt, Hugo T., *78
 Engstrom, W. W., *337
 Estes, E. H., Jr., *425
 Etheridge, Charles L., *425
 Eugenio, Teodora M., *156, *514

F

Fair, John R., *150
 Fajans, Stefan S., 83-88, 194-201, 215-219
 Farkas, T. G., *233
 Farquhar, James W., *75
 Farquhar, Marilyn G., *150, *425
 Feinberg, Leonard, *513
 Field, James B., *75, 245-249
 Field, R. S., *337
 Fineberg, S. K., *508
 Fisher, R. B., *509
 Fitch, Walter M., *426
 Flinn, Robert B., *422
 Foa, Piero P., *75
 Foley, Joseph B., *514
 Fons, Anthony L., III, *237
 Fønss-Bech, P., *150
 Forbath, M., 311-317
 Forbath, N., 167-169
 Forsell, O. M., *233
 Forsham, Peter H., 324-327
 Forsman, Olof, *233
 Francis, John O'S., 386-391
 Franckson, J. R. M., *233
 Fraser, Russell, *76, *79
 Freeman, D. J., *512
 Freinkel, Norbert, *234, *335
 Friedberg, S. J., *425
 Fry, I. Kelsey, *336

G

Gadek, Raymond J., *153, *428
 Galansino, Giorgio, *75
 Galbraith, H.-J. B., 459-465
 Ganguly, J., *156
 Garland, James, *338
 Garnet, James D., *233
 Gastineau, Clifford F., *335
 Gates, Edwin W., *233
 Gemzell, Carl-Axel, *233, *235, *237
 Georas, Constantine S., *509
 Gepts, Willy, 63-69
 Gerszi, Kornell E., *154
 Ghosh, J. J., *507
 Ghosh, N. C., *507
 Gibbons, Donald M., 416-418
 Giles, Kenneth M., *233
 Gilgore, Sheldon G., 392-393
 Gillmann, H., *426
 Ginsburg, Jean, 459-465
 Girard, Louis J., *507
 Gittleman, I. F., *233
 Gitzelter, Louis, *511
 Givner, Isadore, *335
 Goessner, W., *335
 Goldner, Martin G., 100-103, 220-221
 Goodner, Charles J., *234, *335
 Gorman, C. K., *234
 Goto, Y., *234
 Grace, William J., *510
 Graef, Irving, 416-418
 Granville-Grossman, K. L., *75
 Green, Robert C., Jr., *150
 Greenberg, Stephen R., *76
 Greenhouse, Barnett, 222-224
 Greiss, Frank C., Jr., *335
 Griesse, G. G., *332
 Griffiths, P. D., *428
 Gross, Jack, *156
 Grubbs, Robert C., 170-173
 Guha, B. C., *507
 Guilak, Hooshang, *508

H

Haathi, E., *151
 Hagbard, Lars, 296-302
 Hagedorn, H. C., *234
 Hagen, Jean M., *76
 Haist, R. E., *234
 Hall, James C., *336, *426
 Halmi, N. S., *155
 Hammes, Robert, 481-484
 Hamwi, George J., 170-173, *426
 Hansen, E., 441-446
 Hansen, O., *336
 Hansen, R. G., *424
 Hardegger, B., *428
 Hardwick, Christopher, *336
 Hare, Robert L., *338
 Harlan, W. R., Jr., *425
 Harris, John E., *233
 Harris, Robert H., *234
 Hartmann, Alexis F., Sr., *336
 Hashim, Sami A., 135-138
 Hastings, A. Baird, *339
 Haunz, E. A., *234
 Hausberger, Franz X., *76

Hawkins, R. D., *234
 Haworth, J. C., *426, *509
 Heersma, J. R., *332
 Hellerström, Claes, *509
 Hellman, Bo, *509
 Henneman, Dorothy H., 272-277
 Henneman, Philip H., 272-277
 Hensel, H., *73
 Hernberg, C. A., *156, *336
 Hetenyi, G., Jr., 311-317
 Hiatt, Howard H., *509
 Higgons, R. A., *73
 Hill, John B., *76
 Hines, Carl R., *425
 Hirsch, Maria Loew, 94-96
 Hlad, C. J., Jr., *149, *151
 Hochella, Norman J., 447-453
 Hofstetter, J. R., *151
 Holcomb, Blair, 331-332, *512
 Hollenberg, H. C., *338
 Holling, H. E., *74, *148
 Holowach, Jean, *336
 Holtzman, Charles M., *427
 Hooks, Laura, *508
 Hopper, James, Jr., *150, *425
 Hughes, Ann H., *335
 Hull, John G., *507
 Hurwitz, David, *74, *232, *339
 Huvos, Andrew, *151
 Hyman, Harris, III, *339

I

Iannaccone, Angelo, 229
 Ikkos, Denis, *235, *237
 Ingle, David J., *336, 394-395
 Issekutz, B., Jr., 311-317
 Ito, Tomiko, *76
 Ivory, R. F., *233

J

Jaccottet, H., *151
 Jacobs, A. Gerson, 447-453
 Jacobsohn, Dora, *424, *509
 Jackson, Derrick, *426
 Jackson, W. P. U., 373-378
 Jakobsen, L. Kramer, *336
 Jakobson, Theodor, *337
 Janes, Ralph G., *76
 Johnson, Nadine K., *76
 Johnson, Philip C., 454-458
 Johnsson, Sven, 1-8
 Jokipii, S. G., *337
 Joplin, G. F., *76, *79
 Jow, E., *73
 Julian, Desmond G., *512
 Jungner, I., *232

K

Káldor, Antal, 126-128
 Kalk, H., *76
 Kantrowitz, Paul A., *232
 Karlsson, Ka., *337
 Kato, J., *234

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
 July-August, 245-344

March-April, 83-162
 September-October, 345-440

May-June, 163-244
 November-December, 441-522

AUTHOR INDEX 1960

Keiding, Nils Rud, *151
Kekwick, A., *235
Kempner, Walter, *152
Kerr, R. B., *74
Kim, Jae Nam, 114-117, 396-404, 490-493
Kimbél, Philip, 447-453
Kimmel, J. R., *79
King, Edward J., *78, *153, *428
King, Francis P., *509
Kinsell, L. W., *235
Kleefield, Elmer, 222-224
Kleeman, Charles, 207-214
Knapp, John, *75
Knauff, H. C., *427
Knowles, Harvey C., Jr., *235
Koenig, Elizabeth, *235
Konig, A., 311-317
Korner, A., *510
Korting, G. W., *335
Krall, Leo P., 220-221, *510
Kravitz, Charles H., *152
Kruger, Fred A., 170-173, 178-182
Kurtz, Martin, *427

L

Lamar, Carlos P., *236
Lambert, Thomas H., 220-221
Lauritzen, Erik, 20-24
Law, Augusta F., *429
Lawrence, A. M., *427
Lazarow, Arnold, 114-117, *236, 396-404, 490-493
Lazarus, Sydney S., 53-62, 118-125, *156, 174-177, 264-271, *427
Leboeuf, Bernard, 261-263, *332, *422
LeCompte, Philip M., *427
Lee, Norman D., *77
Leemann, W., *74
Levy, Carroll M., *510
Lennon, E. J., *337
Leonards, J. R., *236
Lerman, Sidney, *152
Levin, Ephraim Y., *423
Levine, Rachmiel, *148
Levitin, Howard, *74
Lewis, J. G., *421
Lewis, R. F., *332
Lindeman, Robert D., 110-113
Lingjoerde, P., *429
Linton, Adam L., *237
Lluch, M., *511
Lockhart, George, III, *153
Logothetopoulos, John, 31-37, *236, 278-285
Lohse, F., *337
Lorentzen, S. E., 441-446
Lorenze, E. J., *73
Louis, Lawrence H., 194-201
Luft, Rolf, *235, *237
Lukens, Francis D. W., *340
Lund, Flemming, *511
Lundbaek, K., 441-446

M

MacDonald, Mary K., *77
Mach, Bernard, *337

Maclean, Neil, 38-47
Madison, Leonard L., 202-206, 215-219, *337
Mahallawy, M. Nagy el, *428
Mahler, Robert, *339
Mallory, G. Kenneth, *338
Mancall, Elliott L., *75
Marble, Alexander, 225-227
Marcó, Alicia, *425
Margolin, Morris, *428
Markkanen, Antti, *510
Marks, I. N., *77
Marks, Paul A., *73
Marques, Maria, *423
Martin, Donald B., *73
Martin, F. I. R., *236
Masley, Peter M., *510
Maxwell, George M., *512
Mayer, Jean, 63-69, *340
McCullagh, E. Perry, *427
McGavack, Thomas Hodge, *152, *237
Meder, V., *428
Meier, Hans, 485-489
Meilman, Edward, *427
Meissner, George F., *509
Menin, William, *152
Menzin, A. William, *339
Merik, Elo, 186-193
Metz, Robert, 89-93
Meyer, W. H., Jr., *77
Michaels, Deurel D., *235
Miller, A. Pidd, *508
Miller, David I., 48-52
Miller, Emery C., Jr., 104-105, 220-221
Miller, Malcolm R., 318-323
Miller, Max, 186-193, *507
Min, Byong Sok, *513
Mitchel, Stanley, 106-109
Mitchell, Marvin L., *77
Mituki, Ide, *235
Moeller, J., *337
Moinat, Pierre, *149
Montgomery, C. Hunter, *508
Moon, Henry D., *150, *425
Moore, Edward W., *77
Moorhouse, John A., 194-201
Morgan, H. E., 250-253
Moss, James M., *78, *148, *423
Mouratoff, George T., *153, *428
Munkner, C., *237, *337

N

Nakamura, K., *152
Nelson, Don H., *148, *231
Nelson, J. F., *232
Nesbitt, Tom E., *153
Newcomb, Alvah L., *340, *481-484
Newey, H., *337
Nielsen, Meta Damkjaer, *150
Nikkilä, Esko A., *337
Norton, William S., 183-185
Null, F. C., *79

O

Oakley, Wilfred, *426
Odell, Gerard B., *423
Ogilvie, Robertson F., 38-47

O'Gorman, P., *428
Oka, Martti, *510
Olivecrona, Herbert, *237
Olloqui, F. Flores, *153
Olson, Florence E., *235
O'Rourke, Mary E., *77
Orto, L. A., *73
Osler, Mogens, *510, *511
Osman, Laila Mohamed, *428
Owen, John A., Jr., 324-327, 370-372
Oyer, Calvin E., *338

P

Page, Otto C., *338
Paillet, Max, *237
Paine, Richmond S., *75
Palva, I. P., *233
P'an, S. Y., *334
Papenberg, J., *73
Pares, R., *511
Park, C. R., 250-253
Parker, Arthur M., *511
Parsons, B. J., *337
Paton, A., 459-465
Patterson, J. W., *233
Pawan, G. L. S., *235
Pearlman, William, 222-224
Pearson, Elinor, *507
Pedersen, Jørgen, *511
Pei, Yen Fen, *334
Pell, Sidney, 303-310
Peltola, Pentti, *510
Pennisi, J. B., *237
Pennock, L. Lewis, *153
Penttillä, I. M., *237
Perdue, George W., *78
Perkin, Frank Scott, 222-224
Perkoff, G. T., *79
Peschel, Ruth Lohmann, *152
Peterson, Ruth D., *333
Petersson, Birger, *509
Piazza, Eugene U., *339
Pincus, J. B., *233
Planas, J., *511
Pogátsa, Gábor, 126-128
Politzer, W. M., *428
Pollack, Herbert, 145-146
Pöllänen, L. O., *237
Pollen, Richard H., 25-30, *340
Pomeranze, Julius, *78, *153, 220-221, *428
Ponz, F., *511
Pope, Charles H., Jr., 9-13
Pote, William W. H., Jr., *511
Power, Marschelle H., *335
Pratt, O. E., *338
Protas, Maurice, 222-224
Pugh, Daniel E., *339
Pulliam, Robert P., *148

Q

Quinlan, Carroll B., *334

R

Raben, M. S., *338
Radding, Robert S., 222-224

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
July-August, 245-344

March-April, 83-162
September-October, 345-440

May-June, 163-244
November-December, 441-522

AUTHOR INDEX 1960

Rahmat-Ullah, Khalil Ahmed, *428
 Rakel, Robert E., *78
 Ralli, Elaine P., *511
 Ramsay, Andrew J., *76
 Randall, Raymond V., *237
 Ranke, Eugene J., *153
 Reeves, William J., 104-105
 Reichard, George A., 447-453
 Reiner, Leopold, *340
 Reinikainen, M., *511
 Renold, Albert E., *78, *148, *231, 324-327, *332, *340, 405-415
 Reynolds, Frank W., *237
 Rice, Carl O., *512
 Ridolfo, Anthony S., 48-52
 Riffield, Lewis, *333
 Riggs, Byron L., Jr., *237
 Ringsted, Jørgen, *511
 Roath, Stuart, 106-109
 Robbins, Jacob John, *423
 Robbins, Stanley L., *338
 Robertson, James, *338
 Robin, Eugene D., *512
 Rocha, Heonir, *151
 Rodari, T., *512
 Rogers, Frank A., *428
 Rogers, Wayne R., *512
 Rook, Arthur, *512
 Root, Howard F., *421
 Rose, Vera, *338
 Rosevear, John W., *335
 Ross, Eric J., *78
 Rowe, George G., *512
 Rubin, Robert, *75
 Rubini, Milton E., *79
 Runge, Walter, 396-404
 Runyan, John W., Jr., *232
 Rush, Thomas, *513
 Russek, Henry I., *338

S

Sabour, Mohamed Sadek, *428
 Sachsse, B., *426, *513
 Sadek, Samir Hanna, *428
 Salter, James M., 31-37, *236, 278-285
 Sandberg, Herschel, *513
 Sasaki, Y., *234
 Schacter, H., *234
 Schaffner, Fenton, *232
 Schlayer, Clotilde, *152
 Schliack, Volker, *79
 Schmertzler, E., *233
 Schmid, R., *339
 Schneider, Jurg A., *334
 Schneider, T., *428
 Schrade, W., *428, *513
 Schwartz, William, *513
 Scogin, John T., *508
 Segal, Harold L., *429
 Segal, Stanton, *514
 Seligson, David, *79
 Sellman, J. C., *79
 Seltzer, Holbrook S., *153
 Serif, George S., 163-166
 Sever, John L., 481-484
 Shapiro, Seymour, 178-182
 Sharma, B. B., *236, 278-285
 Sharpey-Schafer, E. P., *514

Shaw, Walter N., *340
 Shay, Harry, *77
 Shea, Stephen M., *338
 Sheridan, Joyce T., 494-499
 Shigeta, Y., *152
 Shoemaker, William O., *339, *429
 Shuman, Charles R., *77
 Sims, Ethan A. H., 363-369, *514
 Siperstein, Marvin D., *514
 Skaug, O. E., *429
 Skillern, Penn G., *153
 Skillman, Thomas G., *78, 170-173, 215-219, *426
 Skovsted, Lis, *150
 Sloan, Norman R., *79
 Smart, T. A., *231
 Smith, Dorothy, *421
 Smith, Marthe E., *339
 Smith, Walter L., *153
 Smyth, D. H., *337
 Snegireff, Leonid S., *429
 Sokal, Joseph E., *154
 Somogyi, Michael, 328-330
 Sordahl, Louis A., *426
 Sørensen, N. Schwartz, *154, *155
 Spanner, Sheila, *231
 Specchia, G., *512
 Spirtos, B. N., *155
 Sprague, Randall C., *155, 419-420
 Spring, Maxwell, *422
 Stadie, William C., *340
 Stadler, G., *339
 Starzl, T. E., *77
 Stearns, Norman S., *74
 Stefko, Paul L., *426
 Stein, Olga, *156
 Steiner, Donald F., *156
 Stephens, John W., *338
 Stewart, Charles J., 163-166
 Stimson, William H., 25-30
 Stone, Martin L., *78
 Strickland, William, *337
 Strickler, J. H., *512
 Stuart, Robert C., *339
 Sugar, Samuel J. N., *156, *514
 Summ, H. D., *339
 Sutherland, Anne B., *507
 Svanborg, Alvar, 296-302
 Swartwout, J. R., *237
 Szinay, Gyula, 126-128

T

Taft, E. B., *337
 Takos, Michael J., *339
 Tanner, Donald C., 25-30, *340
 Tatlier, Serkis, *156
 Taussig, Barrett L., *75
 Taxay, Emil P., 106-109
 Taylor, Fred, Jr., *234
 Taylor, P. J., *514
 Teicke, R., *428
 Thomas, Lawrence J., *156, *514
 Thompson, Marilyn M., *340
 Thorn, George W., *78, *148, *231
 Traisman, Howard S., *340, 481-484
 Tranquada, Robert E., 207-214, 215-219
 Travis, David M., *512

Treibergs, Biurta, *236
 Trout, D. L., *425
 Tupper, C. John, *513
 Tyler, F. H., *79
 Tyler, Russell D., 97-99
 Tyroler, Sidney, *148, *423

U

Umie, Y., *234
 Ungar, Georges, 178-182
 Unger, Roger H., 202-206

V

Vallance-Owen, J., *76, *79
 Van Bruggen, J. T., *340, *425, *429
 Vance, Vernon K., *232
 Van Itallie, Theodore B., 286-291, *429
 Vannas, S., *156
 Villazon, Manuel, 356-362
 Volk, Bruno W., 53-62, 118-125, *156, 174-182, 264-271, *427

W

Wada, M., *152
 Wagner, David H., *514
 Wagner, E. M., *423
 Wakil, Salih J., *156
 Walker, Geoffrey, *235
 Walker, Robert S., *237
 Wallenfels, K., *339
 Warren, K. W., *340
 Washko, Mary E., *429
 Weaver, J. A., *234
 Weinhouse, Sidney, 447-453
 Weinstein, Albert, *157
 Weitze, Marie, *157
 Weller, Charles, 220-221
 Wells, Lemen J., 114-117, 396-404, 490-493
 Welsh, George W., 3rd, 363-369, 466-470
 West, Kelly M., 379-385, 454-458
 Westman, Sighild, *509
 Whipple, N., *149
 White, Priscilla, 222-224, 345-355
 Whitehead, William O., *77
 Whitehouse, Fred W., *157
 Whitner, Virginia S., *334
 Wick, Arne N., 163-166, 178-182
 Wijnmalen, Elisa H. W., 129-134
 Wilkerson, Hugh L. C., *157, 386-391
 Williams, Frederick W., 72
 Williams, Robert H., 25-30, *156, *340, 406-415
 Williamson, Joseph R., 471-480
 Wilson, Jean D., *514
 Winegrad, Albert I., *340
 Wiseman, Ralph, Jr., *77
 Wittels, Benjamin, *340
 Wohltmann, Hulda J., *336
 Wolf, Helmut, *340
 Wolff, M.v., *339

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
 July-August, 245-344

March-April, 83-162
 September-October, 345-440

May-June, 163-244
 November-December, 441-522

AUTHOR INDEX 1960

Wong, Rose K. L., *340, *429
 Wood, F. C., Jr., 261-263
 Woodward, Hiram, Jr., 186-193
 Wrenshall, G. A., *73
 Wright, Peter H., *514
 Wyshak, Grace, *429

Y

Yalow, Rosalyn S., 254-260, 356-362,
 *422
 Yoshida, T., *152

Z

Zachariah, F., *509
 Zachrisson, Ulla, *509
 Zetterström, R., *232
 Zoidis, John, *422

DIABETES: VOLUME 9 PAGE NUMBERS BY ISSUE

January-February, 1-82
 July-August, 245-344

March-April, 83-162
 September-October, 345-440

May-June, 163-244
 November-December, 441-522

Reviewers

BOOKS

Oscar Bodansky, M.D., New York
Thaddeus S. Danowski, M.D., Pittsburgh
Norman W. Drey, M.D., St. Louis
Harvey C. Knowles, Jr., M.D., Cincinnati
Philip M. LeCompte, M.D., Boston

Henry E. Marks, M.D., New York
Kermit E. Osserman, M.D., New York
Herbert Pollack, M.D., New York
Howard F. Root, M.D., Boston
John V. Waller, M.D., New York

MANUSCRIPTS

The Editors of *DIABETES: The Journal of the American Diabetes Association* are grateful to the following persons who, although not members of the Editorial Board during the year 1960, evaluated scientific contributions to the Journal.

George F. Badger, M.D., Cleveland
Solomon A. Berson, M.D., New York
Oscar Bodansky, M.D., New York
Jerome W. Conn, M.D., Ann Arbor
Norman Deane, M.D., New York
Jorn Ditzel, M.D., Glostrup, Denmark

James B. Field, M.D., Bethesda
Martin G. Goldner, M.D., New York
Arnold Lazarow, M.D., Ph.D., Minneapolis
Marvin D. Siperstein, M.D., Ph.D., Dallas
Arthur G. Steinberg, Ph.D., Cleveland
Gerald A. Wrenshall, Ph.D., Toronto

Memoranda

